>>WE'LL JUST HOPEFULLY BE
ABLE TO GET STARTED SOON.
I WOULD LIKE TO RECOGNIZE PEOPLE
WHO ARE RETIRING FROM THE
COUNCIL FOR THE BENEFIT OF OUR
PUBLIC MEMBERS WHO ARE ATTENDING
AT THIS POINT IN THE MEETING.
DR. JENNIFER DEBOW WILL BE
RETIRING DR. MARTHA
[INDISCERNIBLE] WILL BE
RETIRING.
DR. NARLA WILL BE RETIRING AND
DR. KEVIN THOMAS IS GOING TO BE
RETIRING.
AS WE MENTIONED DURING CLOSED
SESSION, NOBODY REALLY GETS
AWAY.
ONCE YOU'VE BEEN A COUNCIL
MEMBER HERE AT THE NHLBI, YOU
ARE A COUNCIL MEMBER AT THE
NHLBI AND WE WILL PROBABLY BE
CALLING UPON YOU.
WE'VE ALREADY EXTENDED YOUR
SERVICE 1 MORE ROUND JUST
BECAUSE IT'S POSSIBLE THAT OUR
SLATE WON'T GET APPROVED ON
TIME.
I KNOW OUR COLLEAGUES AT THE
DEPARTMENT DO THE BEST THAT THEY
CAN BUT THINGS DON'T ALWAYS WORK
AS PLANNED.
SO DR. GIBBONS JUST TO CATCH YOU
UP.
I DID OPEN THE MEETING AND
TALKED ABOUT THE COUNCIL MEMBERS
BUT IF THERE'S ANYTHING YOU
WOULD LIKE TO SAY BEFORE YOU
GIVE YOUR DIRECTOR'S REPORT, I
THINK THAT WOULD BE GOOD.
MAYBE YOU WANT TO TELL EVERYBODY
THAT IT'S OUR 300th MEETING.
SO I DIDN'T DO THAT.
YES, YOU MAY.
DR. GIBBONS WILL GIVE HIS
DIRECTORS REPORT.
>>ALL RIGHT.
WELL, GREETINGS, I DIDN'T GET A
CHANCE TO PUT IN THE GAVEL ON
OUR 300th MEETING OF THE
NATIONAL HEART LUNG AND BLOOD
ADVISORY COUNCIL.
IT IS A KEY MILESTONE.
IT'S A TESTIMONY TO THE FACT
THAT WE'RE CLOSING IN ON THE
75th ANNIVERSARY OF THE NHLBI.
IT'S 1 OF THE EARLY INSTITUTES
OF THE NATIONAL INSTITUTES.
TEST TEST.
CAN YOU HEAR ME OKAY?
TEST TEST.
OKAY?
THEY ALSO LIKE TO GIVE YOU
THIS--I FEEL MORE LIKE A ROCK
STAR WHEN I HAVE THIS ON.
SO THIS IS GREAT.
AND AGAIN, WE APPRECIATE YOUR
SERVICE AND SHARING YOUR
PRECIOUS BRAIN POWER WITH US AND
GIVING US FEEDBACK, THIS WILL BE
A VERY BRIEF DIRECTOR'S REPORT.
ONE WHERE--CAN WE ADVANCE THE
SLIDES?
IS SOMEBODY DOING THAT FOR ME?
I'M PUSHING BUTTONS AND THEY'RE
NOT MOVING.
>>HELP IS ON THE WAY.
>>WELL, IT'S GOOD TO BE IN
PERSON.
[LAUGHTER]
THOSE HABITS I GOT INTO VIRTUAL,
SOMEBODY WAS JUST TAKING CARE OF
ALL THESE THINGS AND I DIDN'T
HAVE TO--I GOT SPOILED DURING
PRESENTATIONS.
OKAY, NOW SOMETHING'S MOVING.
OKAY, THANKS A LOT.
NEXT SLIDE.
GREAT.
THERE'S ALWAYS THESE BITTER
SWEET MOMENTS IN THE COUNCIL
WHERE WE HAVE OUR ROTATIONS AND
TURNOVER.
I JUST WANT TO THANK THOSE WHO
ARE ROTATING OFF FOR YOUR
SERVICE, DRS. DEVOE, GILLET,
NARLA, SCHOFIELD AND THOMAS, WE
APPRECIATE ALL THAT YOU'VE
SHARED WITH US OVER THESE
SEVERAL YEARS AND AS DR. MOEN
MENTIONED, WE KNOW WHERE TO FIND
YOU NOW.
AND YOU ARE ALWAYS PART OF THE
NHLBI LEADERSHIP FAMILY SO WE
CAN APPRECIATE YOUR SERVICE AND
STAND BY BECAUSE AGAIN WE MAY BE
CALLING UPON YOU IN THE FUTURE.
NEXT SLIDE, PLEASE.
AND THEN THE OTHER SWEET MOMENT
IS THAT WE GET TO SAY HELLO AND
WELCOME NEW MEMBERS IN
PARTICULAR THIS ROUND,
DR. FRETZ, DR. SCHNAPP AND
DR. SOLA-VISNER.
WE ARE DELIGHTED TO HAVE YOU
WITH US AND IN THE EARLY EARLY
MEETINGS DR. SCHNAPP, INTRODUCED
PERHAPS A NEW PRACTICE THAT WE
MAY DO PARTICULARLY WITH THESE
HYBRIDS IS 1 OF THE THINGS THAT
BEING IN COUNCILS THAT I RECALL,
WHEN I WAS THERE IS THAT YOU
WOULD OFTEN MEET MAYBE AT THE
HOTEL, THE NIGHT BEFORE, MAYBE
COME OVER TOGETHER ON A BUS OR
SOMETHING, GET A CHANCE TO
SCHMOOZE AND CHAT BEFORE THE
MEETING AND IN BETWEEN THE
BREAKS AND IT WAS NICE TO GET TO
KNOW YOUR COLLEAGUES OFTEN IN
DIFFERENT DISCIPLINES, DIFFERENT
INSTITUTIONS.
DIFFERENT DISCIPLINES OF SCIENCE
AND THAT WAS KIND OF A NICE
THING ABOUT BEING ON COUNCIL.
I THINK WITH THE PANDEMIC AND
THE REMOTENESS, YOU MIGHT HAVE
LOST A LITTLE BIT OF THAT SORT
OF PERSONAL TOUCH AND
ENGAGEMENT.
SO I APPRECIATE THE SUGGESTION
WE HAD THERE FOR A WHILE IN THE
TABLE OF INTRODUCTIONS TO GET TO
KNOW EACH OTHER A LITTLE MORE.
SO THANK YOU FOR THAT.
NEXT SLIDE, PLEASE.
SO JUST A COUPLE OF QUICK TOPICS
WHICH IN ESSENCE WE'RE KIND OF
MELDING A COUPLE THINGS.
WE ALWAYS START OFF WITH,A
COUNTABLE STEWARDSHIP, WE
OBVIOUSLY ARE STILL PROCESSING
FY22 SO I DON'T HAVE FINAL
NUMBERS THERE, BUT THAT WILL BE
NEXT COUNCIL WHERE WE TELL YOU
WHERE WE KIND OF LANDED WITH
FY22 AND IT'S ALREADY TOO EARLY
TO TALK ABOUT FY23 SINCE
CONGRESS AND APPROPRIATORS JUST
BASICALLY MARKED UP THE HOUSE
AND THE SENATE VERSIONS AND
WE'RE INTO ELECTION SEASON.
THERE ARE SOME AT NIH THAT CALL
THAT SILLY SEASON IN THE SENSE
THAT THERE'S A LOT OF
UNCERTAINTY AND I DON'T NEED TO
TELL YOU, I DON'T WANT TO GET
INTO POLITICS HERE BUT THESE ARE
OFTEN TIMES WHERE THE CONTROL OF
THE DIFFERENT HOUSE AND SENATE
POTENTIALLY IS IN PLAY WITH THE
ELECTION AND SOMETIMES THAT CAN
HAVE LIMP IICATIONS FOR OUR
BUDGET AND WHAT WAS MARKED UP
AND WHAT HAVE YOU.
SO THIS IS A PERIOD OF
UNCERTAINTY ABOUT FY23.
WE ARE CURRENTLY UNDER A C. R.,
CONTINUING RESOLUTION, KEEPS US
FLAT TO THE FY22 APPLICATION AND
AGAIN THAT HAS ITS OWN
UNCERTAINTIES SINCE CLEARLY
THERE ARE ADDITIONAL THINGS THAT
HAD PLANNED TO GET DONE IN 2023
AND REALLY WAS HOPING WE WOULD
NOT BE FLAT FOR FY22, SO SEEING
HOW THAT ALL PLAYS OUT WILL BE
OF INTEREST OVER THE NEXT 6
MONTHS.
SO WITH THE NEXT SLIDE, WHAT
WE'RE ALWAYS TRYING TO DO IS
ACHIEVE THAT BALANCE ACROSS OUR
PORTFOLIO, BOTH PROGRAMMATICALLY
IN TERMS OF PRIORITIZING
INVESTIGATOR INITIATED DISCOVERY
SCIENCE IS OUR FOUNDATIONAL CORE
THAT'S MAINLY THROUGH RPGs,
RO-1s AND YOU SEE THAT THAT'S
TD VAST MAJORITY OF OUR
INVESTMENT STRATEGY OVERALL AND
IT'S WE'VE BEEN FAIRLY
SUCCESSFUL BALANCING THAT OUT
FOR THE YEARS AND INSURING THAT
WE'RE ABLE TO KEEP A PRETTY GOOD
PAY LINE IN THE MIDTEENS SO FAR
AND A SUCCESS RATES IN THE 20S
SORE SO, EVEN HIGHER FOR EARLY
STAGE INVESTIGATORS.
THAT'S CHALLENGING GIVEN THE
RISING COSTS OF RO-1S.
THAT HAS OCCURRED AND
DISAPPEARANCE OF THE OLD MODULAR
GRANTS THAT SOME OF US REMEMBER
AND BECAUSE OF AGAIN, THE
INCREASING DOLLARS AND INDEED
THE ONGOING NEED TO ADDRESS NEW
OPPORTUNITIES AND SEIZE
OPPORTUNITIES AND SO WE HAVE TO
MAINTAIN THAT BALANCE OF
CONSISTENCY OF THAT INVESTIGATOR
INITIATED POOL, BUT ALSO BEING
ADAPTIVE TO NEW OPPORTUNITIES
AND NEW NEEDS.
NEXT SLIDE, PLEASE.
TOWARD THE END, I JUST WANT TO
DESCRIBE 1 CATEGORY OF THOSE
AWARDS THAT WERE IN THAT PIE
CHART WHERE WE LEVERAGE FOR SORT
OF RESEARCH AND DEVELOPMENT IN
MANY CASES THAT ARE INSTITUTE
PRIORITIES IN WHICH WE'RE TRYING
TO TAKE A STRATEGIC FOCUS IN
PARTICULAR AREAS OF INVESTMENT
THAT REALLY AREN'T AMENABLE TO
AN INDIVIDUAL RO-1 OR EVEN A PPG
TO ACHIEVE.
AND WHERE WE CAN MOVE NIMBLEY
AND ADAPTIVELY TO ADDRESS A
CURRENT CHALLENGE OR SCIENTIFIC
OPPORTUNITY.
AND SO TYPICALLY THERE ARE
MECHANISMS, SOME OF WHICH YOU'VE
ALREADY SEEN AND APPROVED TODAY
IN DOMAINS LIKE CLINICAL TRIALS,
OUR USUAL RFA P A Rs,
TRAINING, SOME OF THE THINGS WE
DO AS AN ENTERPRISED CO FUND
INITIATIVES AND THOSE OFTEN USE
TRADITIONAL MECHANISMS ARE USED.
BUT THERE'S ALSO RESEARCH WHERE
WE'RE TRYING TO DO SOMETHING
PROBABLY A BIT UNCONVENTIONAL OR
WHERE THERE'S NOT A LOT OF
PRECEDENT AND THIS HAS BEEN
EVOLVING AND THE NHLBI HAS THIS
AUTHORITY TO LITERALLY CALL
OTHER TRANSACTION AUTHORITIES.
AND ITS NAME IS ACTUALLY IN SOME
WAY REGULATORY.
IT'S NOT A TRADITIONAL GRANT
THAT MIGHT BE INVESTIGATOR INIT
YAIOF THED LIKE AN RO-1 WHERE
THE IDEA COMES FROM THE
INVESTIGATOR AND FOR THE MOST
PART THE NIH AND THE INSTITUTE
IS PRETTY MUCH STEWARDS IN A
SENSE OF AT A HIGH LEVEL,
INSURING YOU STAY ON TOP OF YOUR
AIMS AND HAVE PROGRESS TOWARD
THOSE AIMS, BUT WE'RE NOT REALLY
AS ENGAGED IN SHAPING THE
SCIENTIFIC PROGRAM AND THEN SORT
OF INTERMEDIATE TO THAT MIGHT BE
U AWARDS THAT ARE OFTEN
COOPERATIVE AGREEMENTS AND THE
INSTITUTE MOVES IN A BIT MORE
AND IS ENGAGED, SOMETHING LIKE
OUR CLINICAL TRIAL NETWORKS
WHERE THERE'S A LITTLE BIT MORE
OVERSIGHT AND ENGAGEMENT WITH
THE INVESTIGATORS ALONG A
PARTICULAR PATHWAY IN SETTING
PRIORITIES.
OTHER TRANSACTION AUTHORITIES
ALSO DIFFER IN A SENSE THAT IT'S
NOT EVEN A CONTRACT WHERE THE
GOVERNMENT KNOWS EXACTLY WHAT
THE DELIVERABLES AND SCOPE OF
THE WORK IS AND CONTRACTS WITH
AN ENTITY TO GET THOSE SPECIFIC
SETS OF DELIVERABLES BY A
CERTAIN TIMELINE.
IN THE CASE OF OTHER
TRANSACTIONS, IT'S KIND OF
NEITHER FISH OR FOUL, NEITHER
GRANT OR CONTRACT WHERE ELEMENTS
THAT ARE USED TO CREATE THESE
OTHER TRANSACTIONS AND WE
PROBABLY USE THEM MORE OVER THE
LAST 5 YEARS OR SO THAN SINCE
THE INSTITUTE HAS HAD ITS
AUTHORITY, I BELIEVE SINCE THE
70S, SO, NEXT SLIDE.
IN THE SPIRIT OF AGAIN, OUR
ACCOUNTABLE STEWARDSHIP AND
TRANSPARENCY ISSUES I JUST WANT
TO RUN THROUGH THIS GROUP OF
AWARDS THAT WE DO--HAVE BEEN
USING AS PRIMARILY A NIMBLE
RESPONSE TO A RESEARCH
OPPORTUNITY WHERE WE'RE ENGAGING
THE COMMUNITIES, OFTEN DIFFERENT
PARTNERS WITHIN THE COMMUNITY
AND IT HAS A NUMBER OF
UTILITIES, I WON'T GET INTO THE
SAUSAGE MAKING BUT IT IS A VERY
FLEXIBLE KIND OF MECHANISM IN
WHICH WE CAN MAKE A
SOLICITATION, ENGAGE PARTIES
TOWARD A PARTICULAR OPPORTUNITY
AND DO SO FAIRLY RAPIDLY AND
INDEED, IN AN EVOLVING WAY SO
THAT WE MAY FIND INTERMEDIATE
PERIODS OF TIME IN THAT AWARD
PERIOD WHERE THE DIRECTION MAY
SHIFT, THE GOALS AND OBJECTIVES
MAY SHIFT AND WE DO THIS IN CO
CREATION AND COLLABORATION WITH
THE ENTITY AWARDEE, I BELIEVE
THIS HELPS TOWARD CREATING
PROGRAMMATIC PLATFORMS AND
STRUCTURES THAT ARE IPT GREATER
NOVATIVE BECAUSE OF THIS CO
CREATION CAPABILITY, TAPPING
INTO DIVERSE EXPERTISE TOWARDS
SOLVING A PROBLEM BUT DOING IT
IN A WAY WHERE MAYBE WE DON'T
KNOW THE SOLUTION QUITE YET, WE
MAY HAVE TO PROTOTYPE, TRY
THINGS, FAIL, TRY SOMETHING
ELSE, AND COME BACK AND THEN
IMPROVE IT AND SO, IN THAT WAY,
AGAIN CREATE SOMETHING NOVEL,
UNPRECEDENTED AND THEN ANOTHER
ELEMENT OF THE TRANSACTIONS IS
THIS CAPABILITY OF BRINGING
DIFFERENT ENTITIES TOGETHER IN
UNIQUE PARTNERSHIPS AND UNIQUE
CONSORTIA EFFORTS AND THAT THOSE
ARE THINGS THAT ARE AGAIN AREN'T
EASILY RUN THROUGH SOME OF THIS
TRADITIONAL SOLICITATIONS AND
MECHANISMS AND ENABLES US TO
AGAIN MAKE SOMETHING THAT WOULD
PROBABLY NOT HAPPEN
SPONTAKENIOUSLY WITHOUT BOTH THE
INSTITUTES LEANING IN AND
LEVERAGING IN OTHER TRANSACTION
AUTHORITY.
NEXT SLIDE.
SO TOWARD THAT END, 1 OF THE
AREAS WHERE THIS WAS
PARTICULARLY EXERCISED IF YOU
WILL, RELATED TO THE PANDEMIC,
TALK ABOUT UNPRECEDENT, ONCE A
CENTURY KIND OF PANDEMIC WHERE
WE HAD TO MOVE QUICKLY,
LITERALLY, THOUSANDS OF PEOPLE
WERE DYING A DAY.
AND THEY WERE DYING FROM A
RESPIRATORY ILLNESS THAT
AFFECTED THE HEART LUNG BLOOD
SEEP SYSTEMS AND WE HAD TO
RESPOND.
MEMBERS OF COUNCIL ARE WELL
AWARE OF THE EFFORTS OF THE
NHLBI AND AGAIN, GIVE A LOT OF
KUDOS TO THE NHLBI COMMUNITY,
CERTAINLY OUR NHLBI STAFF WHO I
THINK DID AN INCREDIBLE JOB OF
RESPONDING TO THAT PUBLIC HEALTH
THREAT AND CRISIS AND MOVE
QUICKLY, MADE IMPORTANT KROWKSS
THAT WE ALLUDED TO PREVIOUSLY
AND 1 OF THE THINGS THAT ALLOWED
US TO DO THAT MECHANISTICALLY
WAS LEVERAGING THE OTHER
TRANSACTION AUTHORITY AND IN
PARTICULAR WITH PROGRAM PLATFORM
CALLED CONNECTS, IT WAS BASIC
LYE A NETWORK OF NETWORKS WHERE
WE COULD TAKE SEVERAL U-AWARDS
BASICALLY THAT FORMED THE BASIS
OF NETWORKS AND THEN CREATE THIS
OTHER TRANSACTION AUTHORITY
STRUCTURE ON TOP OF THAT TO
AGAIN MOVE THEM TOWARD A NEW
OBJECTIVE AND THE NICE EXAMPLE I
ALWAYS HARKEN BACK TO WAS
GETTINGLET PEDAL NETWORK OF
PULMONARY CRITICAL CARE FOLKS
AND THE CARDIO THORACIC SURGEON
NETWORKS TOGETHER AND AND HAVING
THEM WORK ON THE SAME MASTER
PROTOCOL INVOLVING A VARIETY OF
AGENTS, BUT YOU KNOW MONOCLONAL
ANTIBODIES TO KEEP PEOPLE OUT OF
THE ICO AND ALIVE.
AND SO, THEY WILL LEAN INTO THAT
WITH THE NETWORK OF NETWORKS IN
PART FACILITATED BY
ADAPTABILITY, FLEXIBILITY AND
UNIQUE PROPERTIES OF THE
TRANSACTION, SO IT'S
ILLUSTRATIVE OF THAT KIND OF
CAPABILITY.
SIMILARLY, DURING THE PAN DEMEC
IT WAS QUITE--PANDEMIC, IT WAS
QUITE CLEAR THAT THE VIRUS WAS
EVERYWHERE BUT THE IMPACT WAS
DISPROPORTIONATE TO CERTAIN
POPULATIONS AND COMMUNITIES AND
THERE WAS AN URGENT NEED TO
ADDRESS THAT WITH COMMUNITY
ENGAGED RESEARCH AND THAT'S WHAT
GAVE BIRTH TO A TRANSNIH
PLATFORM THAT NHLBI PLAYED LEAD
ROLE ON IN CREATING AN ALLIANCE
AGAINST COVID-19 DISPARITIES OR
SEAL AND IT WAS EFFECTIVE IN
BRINGING TOGETHER AGAIN A
NETWORK, I THINK THAT NETWORK
EXPLICITLY EXISTED BUT WE HAD
ELEMENTS OF IT AGAIN, SOME OF IT
THROUGH RFAs AND DECIPHER
NETWORK AS WELL AS OTHER
ENTITIES IN THIS AREA OF
RESEARCH THAT WE'RE ABLE TO KNIT
TOGETHER TOWARD THIS PURPOSE AND
MOVE IT QUICKLY AND ADAPTIVELY
AND PARTICULARLY IN THIS CASE,
LEVERAGING ITS ABILITY TO BRING
TOGETHER AUCNIQUE CONSORTIUM.
IN THIS CASE OF COMMUNITY BASED
ORGANIZATIONS, AS WELL AS
ACADEMICS AND OTHER ENTITIES AND
VARIOUS COMMUNITY ORGANIZATIONS.
AND SO, REALLY LEVERAGING ITS
UTILITY AND FORGING THOSE NEW
KINDS OF COLLABORATIONS, AND SO
THAT WAS ANOTHER USE CASE AND
THEN MOST RECENTLY IT'S BEEN
CRITICAL IN NHLBI TAKING A A
LEAD ROLE ON THE NIH EFFORT ON
LONG COVID RECOVER LOOKING AT
POST ACUTE SEQUELACE INFECTION
AND THEY'RE CLEARLY A NOVEL
CONSORTIUM WHERE YOU HAD TO
BRING TOGETHER DISCIPLINES OF
NEUROLOGY, PSYCHIATRY, CARDIO
PULMONARY, A VARIETY OF
DISCIPLINES OF, A VARIETY OF
INSTITUTES, A VARIETY OF
PARTNERS, COMMUNITY ENGAGEMENT,
PATIENT ENGAGEMENT, PRIVATE
SECTOR ALL COMING TOGETHER TO
SOLVE A PROBLEM AND AGAIN IT'S
BEEN VERY USEFUL IN THAT REGARD
NEXT SLIDE, PLEASE EMPLOY MORE
BRINGING IT BACK TO THE NHLBI
PORTFOLIO.
THIS HAS BEEN A VERY USEFUL
PLATFORM FOR CREATING TOP MED
AND BIODATA PLATFORM OF SPACE
THAT CAN ENABLE INVESTIGATORS TO
HAVE ACCESS TO REALLY DATA AT
SCALE AND DEPTH THAT'S
MULTIDIMENSIONAL IN WAYS THAT
QUITE FRANKLY I DON'T THINK WE
REALLY HAD BEFORE WHERE THESE
WERE OFTEN SILOED IN TERMS OF
DIFFERENT DATA SETS AND OFTEN
SEQUESTERS BY THOSE
INVESTIGATORS, SORT OF
DEMOCRATIZE, THEY HAVE ACCESS
AND CAPABILITY AND IS IN A
PLATFORM THAT CAN LEVERAGE
THINGS AT SCALE SUCH THAT
THEY'RE MACHINE READABLE AND
APPLICABLE TO MACHINE LEARNING
AND AI CAPE ABLES THAT
WE--CAPABILITIES THAT WE HOPE
WILL BE A BASIS FOR
COLLABORATIONS, NOT ONLY WITH
THE HEART LUNG AND BLOOD SLEEP
SCIENTISTS BUT OTHERS THAT DATA
SCIENTISTS THAT WILL ACCELERATE
OUR EFFORTS TO FULFILL OUR
MISSION.
THAT'S BEEN A SIZABLE INVESTMENT
AS YOU CAN SEE THERE, AGAIN FOR
TRANSPARENCY OVER THE LAST
SEVERAL YEARS TO BUILD BACK AND
TO MAINTAIN IT AND TO CONTINUE
TO DEVELOP IT SO, IT IS CLEARLY
ANOTHER CONTEXT WHERE, IT
PROBABLY COULDN'T HAVE BEEN DONE
AS WELL, I BELIEVE THROUGH A
GRANT OR EVEN A U OR AT SOME
LEVEL A CONTRACT MECHANISM TO
CLAIM THE BEGINNING SINCE WE
DIDN'T KNOW WHAT IT WAS GOING TO
LOOK LIKE SINCE WE FIRST STARTED
AND WE'RE STILL INVOLVING IT.
SO THAT WAS 1 OF THE AREAS WHERE
WE INVESTED.
SIMILARLY WE LEVERAGED THE O. T.
MECHANISM FOR THE CURE SICKLE
CELL INITIATIVE, THIS IS
OBVIOUSLY AN AREA OF PRIORITY
AND 1 WHERE WE WERE DEALING WITH
A PATIENT POPULATION THAT IS
OFTEN QUITE FRANKLY FELT
MARGINALIZED IN WHICH AGAIN WE
WANT TO DO PARTNERSHIPS AND
DEVELOP THIS WITH PATIENTS AT
THE CENTER AND PATIENTS ENGAGED
AT EVERY LEVEL OF THE PROJECT
INCLUDING THE EXECUTIVE
COMMITTEE WHERE WE'RE MAKING
DECISIONS ABOUT THESE
INVESTMENTS AND INDEED, THIS IS
ALSO AN AREA WHERE WE WEREN'T
SURE WHAT WAS THE BEST STRATEGY
TO CURE AND WHERE INVESTIGATORS
HAD DIFFERENT CONCEPTS, BUT NONE
COULD DO IT ALL BY THEMSELVES.
SIMILARLY IT WAS AN AREA THAT
BIOTECH IS JUST STARTING TO
NIBBLE AROUND ON AND WHERE,
QUITE FRAIRVEGLY, IN TALKING TO
THEM, THERE WAS SOME UNCERTAINTY
ABOUT ENGAGING THIS COMMUNITY
AND USING OR LEVERAGING THIS
OPPORTUNITY TO TEST SOME OF
THESE TECHNOLOGIES SUCH AS GENE
EDITING AND THAT WAS AN
IMPORTANT PART OF THE
COLLABORATIVE PARTNERSHIP,
HAVING FDA AT THE TABLE, BIOTECH
AT THE TABLE, PHARMA AT THE
TABLE, LONG SIDE PATIENTS TO
REALLY BRAINSTORM AND DEVELOP
THIS INITIATIVE.
WE KNEW THAT PATIENT ENGAGEMENT
WOULD ALSO HAVE TO INVOLVE
ENABLING TECHNOLOGIES OF
BIOMANUFACTURING, NEW,A SAYS,
AND NEW APPROACHES.
PERHAPS NEW TECHNOLOGIES AND
CONDITIONING AND GENE THERAPY,
SO WE WANT TO CREATE A PLATFORM
THAT WOULD FACILITATE AND
ACCELERATE AND CATALYZE THAT AND
AGAIN, THAT COULD BE NIMBLE AND
ADAPTIVE AS NEW OPPORTUNITIES
AND NEW TECHNOLOGIES EVOLVED AND
INDEED IT HAS BEEN SUCCESSFUL
AND ENABLING SOME INVESTIGATORS
TO MOVE FROM THINGS THAT WERE
LITERALLY INVITRO TO START UP
COMPANIES THAT ARE IN THIS SPACE
NO.
SO THAT'S A UTILITY I BELIEVE OF
LEVERAGING A NIMBLE AND ADAPTIVE
WAY THE OTHER TRANSACTION
AUTHORITY.
WE ACTUALLY HEARD TODAY SOME
DISCUSSIONS ABOUT CATALYZE IN
TERMS OF THE PINE LINE OF
DEVELOPMENT OF TECHNOLOGIES AND
PRODUCTS AND SO, WE EMBEDDED
THAT OTHER TRANSACTION
CAPABILITY AS A COMPLEMENT TO
THE GRANTS AND CONTRACTS THAT
ARE ALSO IN THE MIX WITH
CATALYZE SO WE CAN ACCELERATE
INNOVATION AND TECHNOLOGY, WHERE
THERE'S OFTEN A NEED TO BE
ADAPTIVE AS YOU DEVELOP AND
INNOVATE.
NEXT SLIDE PLEASE.
SO MOST RECENTLY, A KEY PART IS
ALSO ENGAGING DIFFERENT
PARTNERSHIPS AND WE TALKED
EARLIER ABOUT THE PANDEMIC AND
IT'S DISPROPORTIONATE IMPACT ON
CERTAIN COMMUNITIES CERTAINLY
INDIGENOUS POPULATIONS, AMERICAN
INDIANS, NATIVE AMERICANS HAVE
BEEN DISPROPORTIONATE, HAVE
CONTINUED TO BE
DISPROPORTIONATELY AFFECTED BY
COVID BUT WE ALSO KNOW FROM A
VARIETY OF DISEASES AND
DISORDERS SOME OF WHICH ARE IN
THE NHLBI PORTFOLIO, INDEED THAT
WAS THE GENESIS OF THE STRONG
CART STUDY OVER THE YEARS AND I
THINK DR. FRETZ WAS AN
INVESTIGATOR AND I THINK
DR. FRETZ, YOU WERE ALSO A
TRAINEE UNDER THE HEART STUDY,
SO DURING YOUR CAREER PATH, THAT
PROGRAM HAS BEEN MAINTAINED AND
SO WE BELIEVE IT'S REALLY
IMPORTANT THAT WE HAVE STRONG,
ENDURING RELATIONSHIPS,
CERTAINLY TRAVEL NATIONS THAT
SHOULD BE SOMETHING THIS
RESPECTS THE SOVEREIGNTY OF
THOSE TRIBAL NATIONS AND SO THAT
IS A PARTICULAR, UNIQUE AND
DISTINCT ENGAGEMENT AND
RELATIONSHIP AND TRUST-BUILDING
KIND OF COLLABORATION WITH WE
WANT TO BE VERY THOUGHTFUL IN
PARTNERING AND AGAIN, WE'RE
LEVERAGING THE O. T. MECHANISM
AS WE SEEK TO FURTHER EXPAND
BEYOND HEART STUDY AND THE
NUMBER OF TRIBAL NATIONS THAT
ARE PART OF THAT TO REALLY
ENGAGE IN THESE AREAS SO THE
PARTICULAR INITIATIVE THAT
LEVERAGES THE COMMUNITY ENGAGED
RESEARCH PLATFORM TO EXTEND TO
SOME OF THESE COMMUNITIES, IS
ANOTHER EXAMPLE OF LEVERAGING
THE O. T. ANOTHER IS 1 THAT
INCLUDES OUR EFFORTS IN MATERNAL
HEALTH, GIVING THE HIGH HEART,
LUNG, BLOOD, SLEEP ELEMENTS OF
THE SOME OF THE ADVERSE
PREGNANCY OUTCOMES PREECLAMPSIA,
HEMORRHAGE, [INDISCERNIBLE], ET
CETERA.
WHERE THIS INSTITUTE, I BELIEVE
DOES NEED TO BE ENGAGED AND IN
PARTICULAR BECAUSE OF THIS
AGAIN, STRIKING HEALTH
DISPARITIES THAT EXIST IN THAT
SAME SPACE.
AGAIN, AFFECTING, COMMUNITIES OF
COLOR, AFRICK AN AMERICAN,
LATINO, AND AS WE ENGAGE IN
THOSE PARTICULAR DISEASE AREAS
TO HAVE THAT BASE OF COMMUNITY
ENGAGED ELEMENTS THAT SPAN
ACROSS AND ARE CONSISTENT IN
BILLING OURSELVES AS TRUSTWORTHY
PARTNERS IS AN IMPORTANT ELEMENT
OF THE PROGRAM THERE.
AND SOME OF THAT ALSO BRINGS IN
TRANSNIH EFFORTS SO THIS O. T.
MECHANISM IS NOT ONLY AVAILABLE
TO NHLBI RESOURCES BUT BRINGING
IN RESOURCES FOR SHARED PURPOSE
ACROSS THE NIH ENTERPRISE.
AND THE FINAL 1 I WILL MENTION
RELATES TO CLIMATE AND HEALTH
WHICH OBVIOUSLY EVERYONE IN THIS
ROOM IS A CLEAR AND PRESENT
EXSTENTIAL THREAT AND WILL ONLY
GET WORSE AND AGAIN INVOLVES
HEART, LUNG AND BLOOD SCIENCE
AND WE NEED TO MOVE, WE NEED TO
ADAPT, WE NEED TO BE NIMBLE AND
WHERE WE NEED TO MAKE
INVESTMENTS, IN A COLLABORATIVE
FASHION AND SO WE ARE ABOUT TO
ROLL OUT A MULTIRESEARCH
OPPORTUNITY ANNOUNCEMENT IN THAT
SPACE AND LOOK FORWARD TO
FORMING A PLATFORM THAT NOT ONY
INVOLVES THOSE OF OTHER
INSTITUTES BUT PARTICULARLY
APPROPRIATIONS, RELATED TO
CLIMATE AND HEALTH THAT IS BEING
CONTEMPLATED BOTH IN THE
PRESIDENT'S BUDGET AS WELL AS
THE HOUSE AND SENATE MARK-UPS.
SO I WANTED TO GIVE YOU THAT
SENSE OF WE'RE USING OTHER
TRANSACTION AUTHORITY, AND HOW
IT FITS IN WITH SOME OF THE
PROGRAMMATIC PRIORITIES IN A
TRANSPARENT WAY.
NEXT SLIDE, PLEASE.
SO LET ME JUST CONCLIEWTD.
NEXT SLIDE, PLEASE WITH GETTING
READY FOR THE ANNIVERSARY, THE
75th ANNIVERSARY OF THE NHLBI.
NO I WAS NOT THERE AT ITS
INCEPTION.
[LAUGHTER]
BUT CERTAINLY WE ARE
APPRECIATIVE OF THE PROUD LEGACY
OF THE NHLBI.
WE STAND ON THE SHOULDERS OF
GIANTS AND IT'S A PRIVILEGE OF
PUBLIC SERVICE TO BE AT THIS KEY
MILESTONE.
DOES ANYBODY KNOW IS THIS LIKE
DIAMOND JUBILEE, I DON'T KNOW
WHAT YOU GET FOR YOUR 75th.
>>YOU HAVE TO BUY ALL THE STAFF
DIAMONDS GARY?
>>[LAUGHTER]
>>DR. MOEN THERE MUST BE A RULE
AGAINST THAT?
SOME LAW?
[LAUGHTER]
>>[INAUDIBLE RESPONSE FROM
COUNCIL ]
>>THAT'S GOOD.
>>I THINK YOU CAN BUY FOR US
BUT WE CAN'T BUY FOR YOU, THAT'S
THE WAY IT WORKS.
>>AND OF COURSE I'M NOT PAID
ENOUGH TO DO THAT AS I PUBLIC
SERVICE ANT SO, BUT I WILL SAY
THIS, GIVES FOLKS AN OPPORTUNITY
TO CELEBRATE THE INCREDIBLE
ACCOMPLISHMENTS OF THE NHLBI AND
THE COMMUNITY AND THE STAFF IN
PURSUIT OF OUR MISSION.
AND I ALSO THINK IT'S REALLY
CRITICAL THAT WE HAVE TO LOOK
FORWARD, BECAUSE I'M ALWAYS
EXCITED ABOUT THE OPPORTUNITIES
THAT WE HAVE BEFORE US SO WE
WILL BE ENGAGING THE COUNCIL AND
BOARD OF EXTERNAL EXPERTS TO BE
IN THIS PROCESS, THE 75th
ANNIVERSARY AND TO TAKE IT AS A
MOMENT TO KIND OF STEP BACK A
BIT.
TAKE A RELOOK AT THE STRATEGIC
VISION THAT YOU WERE ALL PART OF
FORMULATING ABOUT 6 YEARS OR SO
AGO.
THE INTENG AT THAT TIME WAS FOR
IT TO NOT SIT ON THE SHELF AND
GATHER DUST BUT RATHER TO REMAIN
EVER GREEN.
INDEED MANY OF HAVE YOU BEEN ON
THE COUNCIL FOR A WHILE
RECOGNIZE THAT THAT'S PART OF
THE OBJECTIVES OF THOSE ANNUAL
RETREATS, OR GATHERINGS OF B
COUNCIL IN SEPTEMBER OF WHICH WE
PERIODICALLY AND HOPEFULLY,
SOMEWHAT SYSTEMATICALLY GO
THROUGH VARIOUS AREAS OF
PRIORITY THAT ENABLES US TO DO A
DEEP DIVE AND A RETHINK AND
PROJECTING FORWARD OF WHAT WE
WANT TO DO RELATED TO THE
STRATEGIC VISION IN A NEW WAY
MOVING FORWARD.
SO WE LOOK FORWARD TO ENGAGING
IN THIS PROCESS, IN THE CALENDAR
YEAR OF 23 AND INDEED,
ANTICIPATE THAT SEPTEMBER SORT
OF GATHERING OF B COUNCIL NEXT
YEAR WILL FOCUS IN ON OUR
STRATEGIC VISION AND THAT
REFRESH TO KEEP IT EVER GREEN IN
WHICH WE OPEN TO LOOK AT SOME OF
THE SCIENTIFIC OPPORTUNITIES,
THE OPPORTUNITIES FOR GETTING
TOGETHER DIVERSE PERSPECTIVES
AND DIFFERENT DISCIPLINES TO
THINK OF THINGS IN A UNIQUE AND
BOLD WAY SO WE'LL BE ENGAGING
YOU IN SOLICITING THOSE BOLD
IDEAS FOR FUTURE DIRECTIONS AND
MEETING CONSTITUENTS AND
STAKEHOLDERS TOWARDS THAT SHARED
VISION ASK CELEBRATING AGAIN
WHAT WE HAVE ACCOMPLISHED AND
WHAT WE CAN DO NEXT THAT WILL BE
OUR SET OF MOON SHOTS AND
ELEMENTS THAT CAN MAKE AN
IMPACT.
NEXT SLIDE.
SO WITH THAT I JUST WANT TO
AGAIN THANK YOU AND I APPRECIATE
THE SERVICE OF ALL THOSE
ROTATING OFF AS WELL AS
WELCOMING THE NEW COMERS, AND
ROLL UP YOUR SLEEVES BECAUSE
THIS WILL BE THE PREPARATION FOR
THE REFRESH OF THE STRATEGIC
VISION IN THE NEXT COUNCIL
SESSIONS.
AND WITH THAT, THANK YOU.
>>WELL, THANK YOU DR. GIBBONS,
THAT WAS LOVELY.
[ APPLAUSE ]
DOES ANYBODY HAVE ANY QUESTIONS
OR COMMENTS ABOUT DR. GIBBON'S
REMARKS?
I THINK EVERYBODY'S GOING TO BE
PROCESSING THOSE FOR A LITTLE
WHILE.
I'M NOT SEEING ANY QUESTIONS FOR
YOU DR. GIBBONS.
SO SINCE WE DON'T SEE ANY
QUESTIONS.
I THINK WHAT WE WILL DO IS WE
WILL CALL OUR COLLEAGUES UP FROM
DECISION LENS AND BRUCE, MAYBE
YOU CAN KICKOFF THE PLANS FOR
DECISION LENS REFRESHER
TRAINING?
>>SO GOOD MORNING EVERYONE AND
SO HAPPY TO SEE EVERYONE TODAY.
PAT'S JUST GETTING SET UP TO GET
STARTED ON THE REFRESHER SO JUST
GIVE US A MINUTE TO GET INTO THE
ZOOM.
>>SO DID YOU HAVE A QUESTION
GARY, SO FOR THE 75th
ANNIVERSARY ARE YOU GOING TO
HAVE A CELEBRATORY 75th
PERCENTILE PAY LINE FOR IT?
[LAUGHTER]
>>I DON'T THINK ANYBODY SCORES
THAT LOW.
>>THAT'S GREAT.
ACTUALLY, YOU KNOW, THOSE ARE
SOME OF THE THINGS THAT WE CAN
ACTUALLY WRESTLE WITH A BIT,
MEANING HOW CAN WE BE THOUGHTFUL
ABOUT INSURING THAT WE'RE MAKING
THOSE INVESTMENTS THAT WILL HAVE
THE GREATEST IMPACT AND SOME OF
IT DOES RELATE TO OUR
STEWARDSHIP OF THE BIOMEDICAL
WORKFORCE AND THINKING THROUGH
HOW WE CAN BE MORE INCLUSIVE
QUITE FRANKLY IN EVERYTHING WE
DO SUCH THAT THE BREDTH OF
INSTITUTIONS THAT ARE
REPRESENTED WITH OUR PORTFOLIOS
THERE, NOT AGAIN FOR ANY SENSE
OF POLITICAL CORRECTNESS BUT
THAT AGAIN TALENTS ALL OVER THE
COUNTRY.
IT'S NOT NECESSARILY LIMITED TO
THE BAY AREA IN BOSTON, EVEN
THOUGH I WAS ON FACULTY AND
INSTITUTIONS THAT ARE IN BOSTON
AND WE THINK ABOUT HOW WE'RE
GOING ABOUT CREATING OUR
NETWORKS, CREATING OUR
CONSORTIUM, CREATING OUR
MULTIUSE SUPPORT TEAMS IN
THINKING THROUGH HOW WE CAN GET
MORE PERSPECTIVE ANDS
DISCIPLINES AT THE TABLE BECAUSE
I BELIEVE THAT THE MOST
CHALLENGING OPPORTUNITIES THAT
WE NEED TO SEIZE NESESITATES
THAT KIND OF GREATER INTERACTION
AND CROSS FUNCTIONALITY, SO THAT
WILL BE 1 OF THE THINGS THAT
ACTUALLY WILL PUT ON THE TABLE
FOR US TO WRESTLE WITH IN
SEPTEMBER.
BECAUSE AGAIN THE TEAMS ARE THE
NEXT 5-10 YEARS WITH THE
OPPORTUNITIES IN COMPUTATIONAL
BIOLOGY, COMPUTATIONAL MEDICINE,
SOCIAL DETERMINE NABTS OF HEALTH
ALL NECESSITATE THAT SO IT'S A
CRITICAL QUESTION AND CHALLENGE
THAT WE NEED TO,A PLIE AND THAT
WOULD BE A GOOD REFRESH ISSUE,
SO I PROBABLY WENT FURTHER THAN
YOU WANTED TO GO WITH THAT
COMMENT AND QUESTION BUT THOSE
ARE THE THINGS ID LIKE US TO
THINK BOLDLY ABOUT SO I
APPRECIATE THAT.
>>CAN I FOLLOW ON WITH THAT,
MERCEDES [INDISCERNIBLE].
I THINK YOUR COMMENTS ABOUT
INSURING STEWARDSHIP AND
SPREADING IT AROUND THE COUNTRY
IS PARTICULARLY IMPORTANT FOR A
NUMBER OF REASONS.
I DO SEE OBVIOUSLY IN SITTING IN
THIS SECTION FROM THAT LENS
THERE ARE THOSE WONDERFUL R15
AREA AWARDS WHICH ARE GREAT,
HOWEVER, YOU KNOW QUALITY OF
THOSE APPLICATIONS COMING FROM
INSTITUTIONS THAT DON'T HAVE THE
RESEARCH ADMINISTRATIVE
INFRASTRUCTURE TO INSURE THAT
THE INSTRUCTIONS ARE FOLLOWED
VERY WELL.
THEY DON'T HAVE A LIBRARY OF
SUBASSESSESFUL EXAMPLES OF SUCH
FUNDING.
THOSE DON'T ALWAYS END UP
SCORING VERY WELL AND THEN THE
GOAL OF THAT PARTICULAR
MECHANISM ISN'T MET AND I THINK
A REAL OPPORTUNITY IS LOST
BECAUSE THESE ARE OFTEN TEACHING
INTENSIVE INSTITUTIONS AND YOU
CAN ALMOST SEE YOURSELF
DISSUADING AN ENTIRE GENERATION
OF HIGH SCHOOL STUDENTS WHO
CHOOSE TO GO IT A TEACHING
INTENSIVE COLLEGE BUT THEY DON'T
EVER HAVE AN OPPORTUNITY TO
ENGAGE WITH NIH FUNDED
RESEARCHERS AND PARTICIPATE IN
THE TYPE OF RESEARCH STUDIES
THAT THEY NEED TO GIVE THEM A
LEG UP FOR GRADUATE ADMISSIONS.
AND SO I THINK FINDING WAYS TO
MENTOR THOSE INSTITUTIONS
RESEARCH ADMINISTRATIVE STAFF TO
MENTOR THEIR RESEARCH
DEPARTMENTS ON HOW TO PREPARE
COMPETITIVE APPLICATIONS AND
WHAT TO DO WITH THEM ONCE THEY
HAVE THEM WILL BE THE ONLY WAY
FOR THE GOAL OF THOSE TO BE MET
AND FOR US TO TRAIN A MUCH MORE
DIVERSE SET OF INVESTIGATORS WHO
AREN'T ALL TRAINING AT
UNDERGRADUATES AT RESEARCH 1
INSTITUTIONS.
>>GREAT COMMENT DR. CARNETHON,
AND ACTUALLY THERE'S A PROGRAM,
1 PROGRAM THAT'S IN THE CONTRACT
SPACE FOR NIH.
I TALKED ABOUT RPGs AND OTHER
TRANSACTION BUT ALSO OUR
CONTRACTS, OUR RESEARCH AND
DEVELOPMENT CONTRACTS AND I WAS
STUNNED THAT I THINK THIS IS
TRUE, THE NHLBI HAS THE ONLY
CONTRACT WITH A HISTORICALLY
BLACK COLLEGE UNIVERSITY.
>>YES WE DO.
>>AND AMONGST THE MILLIONS OF
DOLLARS OF CONTRACTS ACROSS NIH
AND THAT'S ACTUALLY APPENDED TO
AN INSTITUTION CALLED
[INDISCERNIBLE], AND I MUST SAY,
AGAIN, THAT WAS MUTUAL BENEFIT
BECAUSE YOU HAVE AN OPPORTUNITY
IN THAT TO ENGAGE UNDERGRADUATES
QUITE FRANKLY LITERALLY COMES TO
THE NIH EVERY YEAR, IT'S 1 OF
THE JOYS, PANDEMIC AFFECTED THAT
IS TO ENGAGE THEM AND GET THEM
EXPOSED.
WITH THE GREAT TEACHING AT THE
INSTITUTION YOU DESCRIBED, THEY
CAN COME TO OUR INTRAMURAL
PROGRAM, YOU KNOW, THE BEST
BIOMEDICAL RESEARCH RESOURCE
THAT EXISTS AND HAVE AN EYE
OPENING EXPERIENCE AND SO THESE
ARE THE KINDS OF THINGS WE CAN
DO TO BROADEN THAT INCLUSIVE
EXCELLENCE.
SOME OF THOSE KIDS THAT I PUT
THEM UP AGAINST ANYBODY AT
HARVARD OR STANFORD.
AND SO THOSE ARE THE THINGS BUT
IT TAKES THAT PROACTIVE OUTREACH
TO MAKE THAT HAPPEN AND AS
DR. MOEN INDICATED THERE IS A
PARTICULAR PROGRAM, YOU SAID PI?
>>PEI.
>>THE PCEREBELLUMS I.
>>THEY HAVE A SPECIAL WEBSITE,
SPECIAL WEBINARS FOR THE HBCUs
IN PARTICULAR, THEY HAVE A
DATABASE, THEY TRY TO CONNECT
THEM WITH MENTORING ACTIVITIES
IF THERE ARE--IF THERE'S A NEED
FOR THAT, THEY'RE VERY
INTERESTED IN INCREASING THE R&D
CONTRACTS COMING FROM
UNDERREPRESENTED SCHOOLS AND SO,
I THINK THAT'S REALLY IMPORTANT.
DR. GIBBONS I HAVE TO
INTERRUPTED.
I THINK WE NEED TO GET BACK ON
TRACK WITH OUR DECISION LENS
STUFF BECAUSE WHAT I WOULD LIKE
TO DO IS HAVE OUR REFRESHER
TRAINING AND THEN WE'LL BREAK
QUICKLY SO EVERYBODY CAN GO OVER
TO THE CAFETERIA BEFORE WHATEVER
RUSH HAPPENS AT THIS TIME OF DAY
TO GRAB LUNCH AND BRING IT BACK
AND THEN WE WILL FOCUS ON
CLEARING OUR CONCEPTS.
>>THANK YOU DR. MOEN, GOOD
MORNING EVERYBODY, MY NAME IS
PAT QUIN, I'M A SENIOR CUSTOMER
SUCCESSFUL FROM DECISION LENS
AND I AM HERE TO PROVIDE A BRIEF
OVER VIEW ON THE DECISION LENS
PLATFORM.
AS MANY YOU KNOW SINCE WE'VE
BEEN DOING THIS FOR A WHILE NOW,
DECISION LENS IS BASICALLY A
DATA SCIENCE PLATFORM THAT THE
NHLBI USES TO CONDUCT THE VOTING
SECTION AND COLLECT THE INPUTS
OF THE VARIOUS SUBJECT MATTERS
FROM THE ADVISORY COUNCIL MY
ROLE AS THE SENIOR SUCCESS
CUSTOMER SERVICE MANAGER IS TO
PROVIDE A COMBINATION OF THIS
REFRESHER TRAINING AND ALSO
TECHNICAL SUPPORT THROUGHOUT THE
DAY SO IF YOU HAVE ANY ISSUES,
FOR THE INDIVIDUALS HERE IN THE
ROOM, PLEASE FEEL FREE TO GRAB
MYSELF OR MY COLLEAGUE BRIAN
RIGHT HERE AND IF YOU ARE A
VIRTUAL ATTENDEE, I HAVE 2 OF MY
COLLEAGUES SUPPORTING THIS
VIRTUALLY AS WELL, LAURA SING
AND PATRICK GEIGER AND THEY ARE
ON THE ZOOM AND THEY WILL HELP
YOU OUT ONLINE AS L. TO PROVIDE
A QUICK REFRESHER ON DECISION
LENS, FIRST OF ALL HERE ABOUT 10
MINUTES AGO, YOU SHOULD HAVE
RECEIVED AN E-MAIL SAYING THAT
THE SESSION IS OPENED.
YOU CAN USE THE LINK IN THAT
E-MAIL TO OPEN THE VOTING MODULE
DIRECTLY.
I WOULD ENCOURAGE YOU TO MAKE
SURE YOU USE EITHER GOOGLE
CHROME OR MOZILLA FIRE FOX AS
YOUR BROWSER, WE HAVE THE MOST
SUCCESS WITH, IF YOU USE EDGE OR
INTERNET EXPLORER YOU MIGHT HAVE
TECHNICAL ISSUES.
SO I STRONGLY ENCOURAGE USING
CHROME OR FIRE FOX AS A
PREFERRED BROWSER.
WHEN YOU LOOKIN LOOK--LOG-IN, E
SECTION YOU WILL, IF YOU NEED TO
CHANGE YOUR PASSWORD, CAN YOU DO
SO WITH THE I FORGOT MY
PASSWORD, AND YOU CAN CLICK
THERE AND THEY WILL GIVE YOU
ACCESS AND IF YOU HAVE ISSUES
WITH THAT, LET ME KNOW.
WHEN YOU LOG-IN YOU WILL COME TO
A PAGE THAT LOOKS SIMILAR TO
WHAT I HAVE UP HERE, THAT THE
MAIN FEATURE I WANT TO CALL YOUR
ATTENTION TO IS THIS MY TASK
SECTION WHERE YOU'LL SEE THIS
TASK, WHERE YOU SEE PORTFOLIO
TITLED IDT OCTOBER 2022 COUNCIL.
YOU CAN OPEN UP BY CLICKING ON
THE RIGHT ALTERNATIVE TASKS
RIGHT THERE AND THIS WILL BRING
YOU TO THE LANDING PAGE TO START
THE RATING SECTION WHERE WE WILL
REVIEW EACH OF CONCEPTS.
WHEN YOU GET IN HERE, YOU WILL
SEE THIS TAB THAT SAYS 14
ALTERNATIVES, THAT'S THE LIST OF
THE 14 CONCEPTS THAT WILL BE
COVERED HERE AFTER LUNCH AND
THOSE WILL BE THE 1S THAT WE'RE
GOING THROUGH AND THEN YOU ALSO
SEE ANOTHER TAB THAT SAYS SIXTH
CRITERIA, THIS IS THE SIXTH
DIFFERENT CRITERIA THAT WE'RE
EVALUATING EACH OF CONCEPTS HERE
IN THE SESSION.
IN ORDER TO GET STARTED, YOU CAN
JUST GO AHEAD AND NAVIGATE TO
THIS ORANGE BUTTON THAT SAYS
START READING ALTERNATIVES AND
CLICK THAT.
AND THAT WILL BRENG YOU DIRECTLY
INTO THE VOTING PAGE AND THIS
WILL BE IN THE ORDER THAT THE
CONCEPTS ARE REVIEWED THROUGH
THROUGHOUT THE DAY.
SO YOU WILL SEE RIGHT OFF THE
BAT OUR FIRST 1 IS 2805, A FEW
THINGS ABOUT THIS MODULEOT TOP
OF THE PAGE, YOU WILL SEE IN
BLUE TEXT IS THE NAME OF THE
CONCEPT THAT YOU'RE CURRENTLY
REVIEWING AND BELOW IT IN THE
PURPLE TEXT IS THE CRITERIA THAT
YOU ARE REVIEWING IT AGAINST.
IN ORDER TO MAKE YOUR VOTING
SELECTION IN HERE, ALL YOU HAVE
TO DO IS SELECT WHICH OF THE
OPTIONS BEST SATISFIES YOUR
ASSESSMENT OF THAT, OF THAT
CONCEPT AGAINST THE CRITERIA.
CLICK IT SO IT HIGHLIGHTS IN
GREEN AND THEN YOU WILL SEE HERE
IN ORANGE AT THE BOTTOM THE NEXT
BUTTON IS NOW HIGHLIGHTED AND
YOU CAN ADVANCE TO THE NEXT
SLIDE.
AND YOU WILL SEE RIGHT HERE
WE'RE STILL ON 2805, THIS IS THE
NEXT CRITERIA TO WHICH THE NEXT
CURRENT OR OPPORTUNITY IS NOW
BEING ADDRESSED.
TO MAKE ANOTHER SELECTION, GO
AHEAD, CLICK NEXT, AND AGAIN
WE'RE ON THE NEXT CRITERIA HERE.
ANOTHER FEATURE I WANTED TO
POINT OUT IS THE BOTTOM CORNER,
YOU WILL SEE THE VIEW COMMENTS
BUTTON.
IF YOU WANT TO ADD ADDITIONAL
CONTEXT TO YOUR SELECTION ON
HERE, CAN YOU CLICK ON THE
COMMENTS BUTTON AND YOU CAN ADD
A COMMENT IN THIS SPACE AS WELL.
ALL YOU HAVE TO DO IS ENTER THE
TEXT, IF YOU WANT YOU CAN MAKE A
SELECTIONOT CATEGORY, ABOUT THE
STRENGTH OR WEAKNESS OF THIS OR
THE INTENSITY AS WELL.
AND THEN YOU CAN USE THAT TO ADD
THE COMMENT IN YOUR OLD REPORT
AND THE TEAM WILL BE ABLE TO SEE
THAT WHEN THEY REVIEW THE
RESULTS AT THE END AND I DO KNOW
THAT THERE WAS ROBUST DISCUSSION
HERE BUT A LOT OF TIMES THE
COMMENTS ARE GOOD FOR THAT AS
WELL WHILE THEY REVIEW THE
RESULTS.
IF YOU DO FEEL LIKE YOU NEED TO
CHANGE 1 OF YOUR RESPONSES, CAN
YOU DO THAT BY JUST ANYTHING
BACKWARDS WITH THE PREVIOUS
BUTTON AND YOU CAN JUST CHANGE
YOUR SELECTION RIGHT THERE.
EVERYTHING THAT YOU DO IN HERE
IS AUTOMATICALLY RECORDED
THROUGHOUT THIS.
IT'S ALL SAVED IN LIVE BECAUSE
IT'S CLOUD-BASED SO IF YOU HAVE
INTERNET ISSUES, OR COMPUTER
PROBLEMS, IT'S NOT A BIG DEAL,
YOU JUST LOG BACK IN AND GET
BACK TO WHERE YOU LEFT OFF AND
CONTINUE.
THE NEXT ITEM I WANT TO SHOW, I
WILL ADVANCE A FEW MORE HERE.
WE'VE BEEN REVIEWING THIS IN
WHAT WE CALL SINGLE VIEW AND
THAT IS WHAT- THAT IS 1 CONCEPT
AND 1 CRITERION THAT WE'RE
EVALUATING IT AGAINST.
ANOTHER OPTION THAT USERS HAVE
IS TO EVALUATE WHAT WE CALL
MULTIVIEW.
NOW MULTIVIEW I WILL CHANGE TO
RIGHT NOW BUT THAT IS GOING TO
PROVIDE YOU WITH THE CONNECTICUT
SEPTORS AND ALL 6 OF THE
CRITERIA THAT YOU'RE EVALUATING
AGAINST AND A LOT OF TIMES
THAT'S EASIER FOR YOU IF YOU ARE
WALKING THROUGH BECAUSE IT HAS
EVERYTHING ON 1 PAGE.
BUT IN ORDER TO NAVIGATE TO
THAT, GO UP TO HERE WHERE THE
PLURIBU TEXT IS, NAVIGATE TO
THIS CIRCLE WITH THE ELLIPSES
THAT SAYS CHANGE OR
ALTERNATIVES, CLICK ON THAT AND
SAY WRITE THIS ALTERNATIVE IN
MULTIVIEW.
YOU WILL ALSO SEE YOU CAN TAKE
THIS YELLOW GUIDED TOUR AND YOU
CAN USE IT OR LOG OUT, CLOSE IT
OUT, NOT LOG OUT.
NOW IN HERE YOU WILL SEE THAT
WE'RE IN THE MULTIVIEW OPTION
WHERE YOU HAVE THE 1 CONCEPT
WHERE YOU HAVE ALL 6 CRITERIA
THAT YOU'RE EVALUATING AGAINST
RIGHT HERE.
THE LAST THING I WILL CALL
ATTENTION TO RIGHT HERE IS IN
THE UPPER RIGHT HAND CORNER, YOU
WILL SEE THE OVERALL PROGRESS
SCREEN, THAT WILL SHOW YOU EVERY
SINGLE INDIVIDUAL CLICK YOU HAVE
TO MAKE, EVERYBODY IN HERE HAS A
TOTAL OF 84 FULL RATINGS THEY
HAVE TO MAKE THAT'S YOUR 14
ALTERNATIVES BY THE SIXTH
CRITERIA IN THERE SO YOU WILL
SEE WITH EACH CLICK IT GOES
AHEAD.
I WILL SHOW THIS A BIT MORE AND
BARRING ANYMORE QUESTIONS THAT
COVERS ANYTHING FOR DECISION
LENS.
IF YOU NEED ANY,A CYSTANCE
THROUGHOUT THE DAY, FEEL FREE TO
GRAB MYSELF OR BRIAN WHO WILL BE
ROAMING THROUGHOUT THE ROOM AND
HELP TRACK PROGRESS.
SO THANK YOU, EVERYBODY.
>>THANK YOU.
IS EVERYBODY LOGGED IN?
DOES ANYBODY NEED HELP WITH
ANYTHING?
SO SINCE WE'RE ALL SET AND READY
TO GO, LET'S STOP QUICKLY.
RUN ACROSS THE HALL, GET
YOURSELF SOME LUNCH, BRING IT
BACK, AND THEN WE'LL GO THROUGH
THE CONCEPTS
>>ACROSS THE DIVISION ASK
INSTITUTE AND ACROSS THE NIH
THAT WE COLLABORATE WITH IN
DEVELOPING THESE, SO THEY'VE
BEEN THROUGH QUITE A BIT OF WORK
STOCK EXCHANGE GET TO THIS
STAGE, ALL OF THESE HAVE CLEARED
BOARDS AND NOW IT'S TIME FOR YOU
TO WEIGH IN ON WHAT YOU THINK OF
THESE IDEAS AND CONCEPTS.
SO THESE WILL BE PRESENTED TO
YOU A LITTLE BIT IN BUNDLES.
I HAVE A COUPLE THAT GO TOGETHER
AND YOU HAVE TO VOTE ON EACH 1
OF THEM, SO YOU'LL HAVE TO PAY
ATTENTION TO WHAT YOU'RE DOING
WITH DECISION LENS BUT WHEN YOU
GO HERE TO SORT OF STREAMLINE
THINGS A BIT, SOME COMMON
COMBINING OF THINGS THAT MAKE IT
EASIER FOR YOU TO UNDERSTAND
WHAT WE'RE PROPOSING.
SO THE FIRST INITIATIVE THAT
WE'RE GOING TO TALK ABOUT IS
INITIATIVES NUMBER 2085 AND 2086
AND BOTH OF THESE ARE ENTITLED
IDENTIFYING THE ROLE OF SLEEP
DEFICIENCY IN PERSONS WITH TYPE
1 DIABETES, SLEEP, GLYCEMIC
CONTROL AND CARDIOVASCULAR RISK
AND THE REASON THERE'S 2 OF THEM
IS THAT THERE'S AN RO-1
INITIATIVE AND THERE'S AN R34
INITIATIVE SO LET ME JUST TELL
YOU ABOUT THE OVERARCHING
OBJECTIVE OF THIS IS TO ADVANCE
OUR MULTIDISCIPLINARY RESEARCH
ELUCIDATING THE CONTRIBUTION OF
SLEEP EFFICIENCY AND CIRCADIAN
DISRUPTIONZ RELATED TO TYPE 1
DIABETES AND RELATED TO
CARDIOVASCULAR DEC PATHOLOGY,
TREATMENT AND RESPONSE.
THE INITIATIVE WAS DEVELOPED IN
ACCORD NATION AND WITH OTHER
COLLEAGUES IN THE HEART PROGRAM
PRIMARILY, BUT ALSO IN THE NIDDK
WHERE THEY HAVE A SPECIAL FUND
WHEN CAN COMES TO THE NIH IN
DEALING WITH THE DIABETES
PROGRAM.
SO IN ESSENCE THIS PARTICULAR
INITIATIVE WILL NOT COST US ANY
MONEY, IT WILL ALL COME FROM THE
SPECIAL DIABETES PROGRAM.
SO LET ME JUST TELL YOU A LITTLE
BIT I DON'T BE HAVE TO SAY
ANYTHING ABOUT TYPE 1 DIABETES.
IT AFFECTS 1.6 MILLION PEOPLE IN
THE UNITED STATES, AND
CARDIOVASCULAR DISEASE IS THE
MOST COMMON CAUSE OF TYPE 1
DIABETES MORTALITY.
SO VERY CLEARLY A HEALTH
PROBLEM.
SLEEP DEFICIENCY IS A COHORT IN
TYPE 1 DIABETES, SO INDIVIDUALS
WITH TYPE 1 DIABETES EXPERIENCE
DIFFICULTY WITH SLEEP DURATION,
TIMING, QUALITY, AND SLEEP
DISORDERS AND PARTICULARLY
LISTENING TO THAT SO IN THE
GENERAL POPULATION, SLEEP
DEFICIENCY IS LINKED TO INHERENT
METABOLIC REGULATION INCLUDING
DPLI SEEMIC CONTROL AS WELL AS
CARDIOVASCULAR DISEASE RISK.
SO THERE ARE MANY ASPECTS OF
SLEEP DEFICIENCY THAT ARE
MODIFIABLE AND SO RESEARCH IS
NEEDED TO ESTABLISH THE
FEASIBILITY OF SLEEP DEFICIENCY
AS A THERAPEUTIC TARGET TO
COMBAT TYPE CONDIABETES TO
FACILITATE MANAGEMENT OF DISEASE
AND IMPROVE OUTCOMES.
SO THIS INITIATIVE IN ORDER TO
ADDRESS THESE GAINS, THIS
INITIATIVE HAS 2 COMPLIMENTARY
PROGRAMS USING THE RO-1 AND THE
R34 MECHANISM.
SO THE RO-1 MECHANISM IS
DESIGNED TO ADVANCE CLINICAL
RESEARCH TO ELUC DATE THE
UNDERLYING MECHANISMS LINKING
SLEEP DEFICIENCY, SLEEP
DISORDERS TO TYPE 1 DIABETES AND
CARDIOVASCULAR PATHOBIOLOGY AND
THAT INITIATIVE IS TOCCATAALIZE
THE TRANSLATION AND PROMOTE
MULTIDISCIPLINARY RESEARCH
BETWEEN A TYPE 1 DIABETES AND
SLEEP AND CARDIOVASCULAR
SCIENTISTS SO ULTIMATELY THESE
STUDIES UNDER THE RO-1 WILL
RESULT IN NOVEL DISCOVERIES
ABOUT SLEEP MEDIATED MECHANISMS
AND TYPE 1 DIABETES AND
CARDIOVASCULAR PATHOBIOLOGY AND
ALSO HOW IT MIGHT BE ABLE TO
TARGET INTERVENTIONS TO IMPROVE
MANAGEMENT AND THE CLINICAL
COURSE OF TYPE 1 WITH
CARDIOVASCULAR DISEASE.
THE R34 MECHANISM RUNS IN
PARALLEL AND THIS IS TO SUPPORT
PILOT STUDIES TO ADDRESS
CRITICAL GAPS IN KNOWLEDGE WITH
RESPECT TO DESIGNING AND
CONDUCTING SLEEP AND CIRCADIAN
BASED INTERVENTIONS IN THE TYPE
1 DIABETES POPULATION, SO
THEREYA I LOT OF EXAMPLES I CAN
GIVE YOU BUT IN THE INTEREST OF
TIME I WILL SKIP THROUGH IT.
BUT YOU CAN SEE THAT THIS
INITIATIVE ADDRESSES THE
ULTIMATE GOAL OF SLEEP AND
CIRCADIAN INTERVENTIONS TO
IMPROVE OUTCOMES IN INDIVIDUALS
WITH TYPE 1 DIABETES AND
CARDIOVASCULAR MORBIDITY.
SO IN UMPIRESRY THIS PACKAGE IS
COMPLIMENTARY PROGRAM REPRESENTS
THE FIRST SLEEP DISORDERED
BREATHING PROGRAM SPECIFICALLY
FOCUSED ON TYPE 1 DIABETES AND
SLEEP.
THE INITIATIVE OBTAINS TO RETAIN
A BETTER UNDERSTANDING OF THE
LINKS BETWEEN SLEEP AND TYPE 1
DIABETES AND A PILOT PROGRAM OF
INTERVENTIONAL STUDIES AIMED AT
SLEEP AS MODIFIABLE FACTOR TO
REDUCE THE ADVERSE CONSEQUENCES
IN PEOPLE LIVING WITH TYPE 1
DIABETES.
SO THE INITIATIVE HAS A
SIGNIFICANT IMPLICATION FOR
CHANGING CLINICAL PRACTICE IF
BEDDING THE ROLE SLEEP PLAYS IN
PEOPLE WITH TYPE 1 DIABETES.
AT THE END OF THE DAY, WE HOPE
THAT WE CAN SUPPORT UP TO 5
RO-1S, 4 R34S, AND OBVIOUSLY THE
REVIEWS WILL BE DONE WITHIN
NHLBI AND ADMINISTERED THROUGH
THE NHLBI AND THE NIH AND IN,
IDDK SO I WILL STOP THERE AND
TRY TO BE HAPPY TO ANSWER
QUESTIONS, IF NOT, DR. AARON
LOPOSKI AT THE NHLBI IS THE MAIN
ORGANIZER AND ARCHITECT OF THIS
PROGRAM AND HE'S AVAILABLE
ONLINE TO ANSWER QUESTIONS, SO I
WILL HOPE IT UP TO ALL OF YOU
FOR ANY COMMENTS ON THIS
INITIATIVE.
>>GO AHEAD DR. SCHNAPP.
>>HI, LYNN SCHNAPP, THANKS.
ONE QUESTION I HAD WHEN I WAS
READING THIS IS, IS THERE
EVIDENT THAT THE SLEEP
DISRUPTIONS IN TYPE 1 ARE
DIFFERENT THAN SLEEP DISRUPTIONS
IN TYPE 2?
SO IT ALSO GOES ON TO DISCUSS
THAT THERE'S A LOT OF RESEARCH
CURRENTLY BEING DONE FOR
CIRCADIAN DISRUPTIONS IN TYPE 2
SO THAT CAME UP TO ME AS A
QUESTION.
>>YEAH, I THINK THAT THERE'S
SOME EVIDENCE THAT IT IS A BIT
DIFFERENT BUT AT THE SAME TIME
IT'S ALSO, THIS IS A TARGETED
PROGRAM, SO WE DON'T--IT DOESN'T
SPILL OVER BETWEEN TYPE 1 AND
TYPE 2.
THIS WAS SET ASIDE SPECIFICALLY
FOR TYPE 1 DIABETES, NOT TYPE 2.
SO YEAH, THE MONIES, AND SO
WE'VE USED THIS AS A VEHICLE TO
REALLY INSERT NOW SLEEP
CIRCADIAN AND CARDIOVASCULAR AS
A PACKAGE TO TRY TO UNDERSTAND
BETTER HOW THOSE INTERFACE WITH
THIS PARTICULAR PART OF THE
DIABETES DISEASE SPECTRUM.
>>NOT SEEING ANY OTHER
QUESTIONS.
>>OKAY, I THINK ALL OF YOU NEED
TO VOTE ON THIS INITIATIVE.
NOW THERE ARE 2, REMEMBER, THE
FIRST 1 IS 2805, AND THE SECOND
IS 2806.
I PACKAGED THEM TOGETHER, 1 IS
THE RO-1, 1 IS THE R34 SO IF YOU
CAN VOTE ON BOTH OF THOSE, THAT
WOULD BE GREAT.
>>HOW ARE WE DOING WITH THE
VOTING?
>>WE STILL HAVE SOME VOTING TO
TAKE PLACE YET.
AND JUST A GENERAL REMINDER
THERE IS 2805 AND 2806, PLEASE.
OKAY, IF YOU ARE READY, WE CAN
MOVE ON.
>>SO GOOD TO GO?
OKAY, YEAH.
OKAY, I SEE THUMBS UP.
GOOD ENOUGH.
SO WE WILL MOVE ON TO THE NEXT 2
WHICH ARE NOT A PACKAGE SO I
WILL DO THESE 1 AT A TIME BUT
THEY'RE BOTH SECONDARY SIGN-ONS
WITH INITIATIVES WITH THE OFFICE
OF RESEARCH ON IMPLEMENTS OF
HEALTH.
SO THE FIRST 1 IS 2822, IT'S
LABELED SECONDARY SIGN-ON FOR
GALVANIZING HEALTH EQUITY
THROUGH NOVEL AND DIVERSE
EDUCATIONAL RESOURCES, RESEARCH
EDUCATION PROGRAM R25.
THIS DID NOT ALLOW CLINICAL
TRIALS.
AGAIN, DR. CHIN LU IS LEADING IT
EFFORT AND CAN CERTAINLY HELP IF
WE HAVE QUESTIONS THAT WE'RE NOT
ABLE TO HANDLE.
SO THIS IS AN R25 PROGRAM AS I
MENTIONED LED BY ORWH AND I CAN
TELL YOU THAT THE GOAL OF THIS
R25 IS TO SUPPORT THE
DEVELOPMENT OF COURSES,
CURRICULA AND METHODS ON TOPICS
RELEVANT TO SEX AND GENDER
INFLUENCES IN HEALTH AND
DISEASE.
I THINK ALL OF YOU KNOW THAT SEX
IS A BIOLOGICAL VARIABLE, GENDER
IS A SOCIAL VARIABLE HOWEVER SEX
AND GENDER BASED GAPS EXIST IN
CLINICAL AND PRECLINICAL
RESEARCH IN ADDITION PROVIDE
TRAINING OF SEX, GENDER AND
WOMEN'S HEGHT IS A GAP AREA FOR
PUBLIC AND THIS IS IN RESPONSE
TO THE REQUEST FOR INFORMATION
THAT HAS COME OUT OF THE OFFICE
OF RESEARCH ON WOMEN'S HEALTH.
SO THEY HAVE SOLICITED THE
COMMUNITY AND FOUND THAT THIS IS
AN AREA THAT COULD USE SOME
ATTENTION.
THE COURSES AND CURRICULA TO BE
DEVELOPED WILL BE WIDELY
DISSEMESTER HADINATED THROUGH
BROAD AUDIENCES,'M EXTENDING
BEYOND THE RESEARCH COMMUNITY
AND REPEATEDLY THROUGH THE ERWH
ELEARNING NETWORK AND PLATFORMS
SO RESEARCHERS AND PROVIDERS CAN
INCORPORATE AND INFORM
PERSPECTIVE ON SEX GENDER IN
THEIR RESEARCH DESIGN AND
CLINICAL PRACTICE.
MANY DEBILITATING HEART LUNG
BLOOD AND SLEEP ORDER DISEASES
DISPROPORTIONATELY AFFECT WOMEN.
I DON'T HAVE TO TELL YOU THAT.
THERE'S ALSO VERY MUCH GENDER
RELATED DISPARITIES, AGAIN,
SOMETHING VERY IMPORTANT TO THIS
INSTITUTE SO THE OBJECTIVE OF
THE SECONDARY SIGN ON IS TO
SUPPORT THE DEVELOPMENT OF THESE
COURSES AND CURRICULA RELATIVE
TO SEX GENDER INFLUENCES AS IT
AMRIS TO HEART, LUNG AND BLOOD
AND SLEEP DISORDERS.
ORWH INTENDS TO COMMIT
1.2 MILLION FUNDS TO SUPPORT 6
AWARDS IN FISCAL 23 AND 24.
SO THE DIRECT CAUSE FOR THESE
ARE RELATIVELY LOW AND THEY'RE
4-YEAR AWARDS.
IN HLBI WOULD COME ON AS A
SECONDARY AND WE WOULD POST 1
AWARD AT 50% FOR A FUTURE
RECEIVE DATE, SO THE TOTAL COST
FOR THIS IS 4 MILLION EACH YEAR
400,000 EACH YEAR.
THAT'S ABOUT IT IF WE NEED TO
CALLOT EXPERTS WE CAN, BUT I
WILL STOP HERE IN CASE THERE ARE
ANY COMMENTS ON THIS CONCEPT.
>>ANY QUESTIONS?
YES?
>>[INAUDIBLE QUESTION FROM
AUDIENCE ]
>>FOR THOSE ON VIDEO HE'S
ASKING FOR CLARIFICATION THAT
THIS IS AN EDUCATIONAL PROGRAM
FOR CURRICULUM DEVELOPMENT.
>>AND THE ANSWER IS YES.
SO AGAIN 2822, YOU'RE VOTING ON
THIS 1.
>>THIS IS LYNN, I ACTUALLY
FOUND THE DESCRIPTION OF THIS
PROGRAM GOAL WAS, WHETHER IT WAS
EDUCATION, PROMOTING RESEARCH, I
CAME AWAY FROM READ THANKSGIVING
AND I'M LIKE WHAT EXACTLY--
>>YEAH, I THINK IT'S EDUCATION.
TO CUT TO THE CHASE HERE.
IT'S TRYING TO GET THE WORD OUT
AS TO WHAT YOU KNOW AND HOW YOU
CAN APPLY.
>>VOTING IS UNDERWAY, JUST A
MINUTE, PLEASE.
>>CAN YOU SPEAK LOUDER ROSE, WE
CAN'T HEAR YOU.
>>I'M SCARED TO SPEAK LOUD
BECAUSE I'M USUALLY HEARD ALL
OVER THE ROOM, BUT I WILL SPEAK
UP, IS THAT BETTER?
>>YEAH, THAT'S OKAY.
>>REALLY GOOD.
>>OKAY.
OKAY, WE CAN MOVE ON TO 3832.
>>ALL RIGHT THANK YOU VERY
MUCH.
WE WILL MOVE TO THE SECONDARY
PARTICIPATION INITIATIVES WITH
ORWH, THIS IS NUMBER 3832.
THIS 1 IS ENTITLED: SECONDARY
PARTICIPATION RENEWAL, I WILL
UNDERSCORE THAT, THE
INTERSECTION OF SEX GENDER
INFLUENCES ON HEGHT RESEARCH,
MAY GET TO YOUR QUESTION NOW.
THIS IS RO-1 CLINICAL TRIAL
OPTIONAL, DR. LAURA
[INDISCERNIBLE] WITH LUNG
DIVISION IS THE WELLED AUTHOR ON
THIS 1 AND HAS REALLY BEEN OUR
CHAMPION WITH RESPECT TO WOMEN'S
HEALTH ISSUES ACROSS NHLBI.
THIS 1 DOES FOCUS ON RESEARCH
AND I WANT TO HIGHLIGHT THAT
THIS IS NOT ONLY SECONDARY
PARTICIPATION BUT IT'S A
REISSUANCE OF THE INTERSECTION
OF SEX AND GENDER INFLUENCES ON
HEALTH AND DISEASE THAT WAS
ISSUED A NUMBER OF YEARS AGO.
THE GOAL OF THIS FOA, THIS
FUNDING OPPORTUNITY ANNOUNCEMENT
REMAINS UPCHANGED AS IT WAS FROM
THE LAST CYCLE WHICH WAS TO USE
THE RO-1 MECHANISM TO STIMULATE
RESEARCH AND ADVANCES ON THE
INFLUENCE OF SEX AND GENDER TO
IMPROVE HEALTHCARE TAYLORED TO
WOMEN OF ALL AGES AND
BACKGROUNDS.
SO, APPLICATIONS RESPONSIVE TO
THIS INITIATIVE MUST INCLUDE
BOTH SEX AND GENDER RELATED
VARIABLES, AND ADDRESS AT LEAST
1 OF THE 5 OBJECTIVES FROM THE
NIH STRATEGIC PLAN FOR WOMEN'S
HEALTH RESEARCH.
I WON'T GO INTO ALL THAT, CAN
YOU FIND THAT ELSEWHERE BUT
AGAIN THIS HAS BEEN A VERY
SUCCESSFUL INITIATIVE IN
PARTICULAR FOR NHLBI.
LET ME HIGHLIGHT A FEW METRICS
WE HAVE COLLECTED AND AS A
RESULT OF THIS INITIATIVE.
LAST CYCLE WE BROUGHT IN 140
APPLICATIONS ACROSS 3 RECEPT
SEEPT DATES FROM 13 INSTITUTES
CENTERS AND OFFICES THAT
PARTICIPATED IN THE FIRST GO
ROUND OF THIS INITIATIVE SO I'M
VERY RESPONSIVE FROM THE
COMMUNITY, THE SET THAT WAS SET
UP HAD SUCCESS RANGE FROM 17-23%
ACROSS ALL OF THE APPLICATIONS.
WHEN YOU HONE DOWN A BIT MORE ON
NHLBI, HERE ARE A COUPLE THINGS
YOU MIGHT BE INTERESTED IN.
WE HAD THE HIGHEST NUMBER OF
TOTAL APPLICATIONS TO THIS RFA,
34 TOTAL APPLICATIONS WHICH
REPRESENT 24% OF THE GRANTS, 36%
OF THOSE FOR THE 2 RECEIVE DATES
WE PARTICIPATED IN AND THE RFA
HAS BEEN REALLY SUCCESSFUL AT
BUILDING CAPACITY AND BRINGING
THE NEXT GENERATION OF
RESEARCHERS INTO SEX AND GENDER
RESEARCH.
SO AT EACH RECEIPT DATE THERE
WAS AN INN CREASE ON BE THE
NUMBER OF ESIs IN THE PROGRAM,
AND THAT REFRECTED THE
APPLICATIONS ASSIGNED AT NHLBI
WITH 45% OF THE RECEIPT DATE
BEING CLASSIFIED AS ESI.
SO FOR OUR PARTICIPATION WE HAD
APPLICATIONS THAT CUT ACROSS ALL
OF THE DIVISIONS AND CENTERS
WITH DIVERSE AREAS OF RESEARCH,
REPRESENTED NOT ONLY IN THE
APPLICATIONS BUT ALSO IN THE
SCIENCE WE FUNDED.
SO VERY, VERY SUCCESSFUL
PROGRAM.
I WANT TO RENEW THIS FOR THE 3
RECEIPT DATES.
WE'VE ASKED FOR DIRECT COSTS OF
350 K PER YEAR, EACH OF THESE
PROGECS WOULD BE UP TO 4 YEARS,
WE ARE REQUESTING TO CO FUND 9
NEW APPLICATIONS IN THIS RENEWAL
AND WE ARE ASKING TO SET ASIDE
$12.6 MILLION.
SO THE FUNDS WOULD ONLY BE SPENT
ON THOSE MERITORIOUSA
APPLICATIONS ON THE FUNDS AND
WOULD OBVIOUS BE USED FOR THESE
PURCHASES, SO THAT PRETTY MUCH
SUMMARIZES THIS PROGRAM WITHOUT
GETTING INTO THE A LOT OF THE
DETALS OF WHAT WE FUNDED
ALREADY, THAT'S SOMETHING WE
COULD DO AT A FUTURE MEETING IF
INTERESTED BUT FOR THIS
INITIATIVE, THAT'S WHAT WE'RE
PROPOSING TO DO WITH THE NEXT
PHASE AND I WILL BE HAPPY TO
AGAIN, TRY TO FIELD QUESTIONS IF
THERE ARE ANY.
>>QUESTIONS?
NOT SEEING ANY QUESTIONS AROUND
THE TABLE, NO QUESTIONS IN THE
CHAT.
>>JUST ANOTHER MOMENT.
WE ARE READY TO MOVE ON TO 2835.
>>SO THE NEXT 2 AGAIN ARE A
PACKAGE SO YOU KNOW YOU WILL DO
THE SAME AS YOU DID WITH THE
FIRST 2.
THIS IS INITIATIVE 3825 AND
3826.
THIS IS ON TITLE SECONDARY
PARTICIPATION IN ALL OF US, AN
RFA THAT'S TITLED ENHANCING THE
USE OF THE ALL OF US RESEARCH
PROGRAM'S DATA.
THIS IS AN RO3 PROGRAM WITH NO
CLINICAL TRIALS AND AN RO21
PROGRAM WITH NO CLINICAL TRIALS.
SO BOTH DR. CHRISTIAN GOMEZ IN
THE LUNG DIVISION AND DR. NICOLE
REDMAN IN THE HEART DIVISION,
AND THEY LED THIS SINCE ITS
INCEPTION, SO THEY ARE THE
BRAINS BEHIND THIS EFFORT.
THIS IS AGAIN, SECONDARY
PARTICIPATION IN THE ALL OF US
PROGRAM, AND ALL OF US AS YOU
KNOW IS AN NIH-WIDE RESEARCH
PROGRAM SO AGAIN THIS TAKES US
OUTSIDE JUST NHLBI.
THERE ARE 2 INIT WHYATIVES, 1 IS
THE 3825 WHICH IS ENHANCING THE
ALL OF US, THIS IS THE RO3 AND
THEN THE SECOND 1, 3826, AGAIN,
SAME TITLE BUT USING A DIFFERENT
MECHANISM, R21.
SO THE RO3 IS QUITE SIMPLE, IT
SUPPORTS PROJECTS USING
ESTABLISHED AND WIDELY ACCEPTED
TOOLS AND METHODS TO ANALYZE THE
DATA IN THE ALL OF US RESEARCH
WORK BENCH, PRETTY STRAIGHT
FORWARD.
THE SECOND 1 IS THE R21, AGAIN
PRETTY MUCH EXPLORATORY TYPE
RESEARCH THAT WILL DEVELOP NEW
METHODS AND MODELS AND TOOLS TO
ANALYZE RESEARCH DATA IN THE
RESEARCH WORK BENCH AND MAKE
THOSE WIDELY AVAILABLE TO THE
COMMUNITY.
SO YOU CAN SEE, THEY'RE VERY
COMPLIMENTARY.
THE ALL OF US PROGRAM INTENDS TO
INVEST A LITTLE OVER 4 MILLION
IN TOTAL COSTS TO FUND ROUGHLY 5
AWARDS IN EACH OF THESE
MECHANISMS FOR A TOTAL OF 10, 2
YEAR AWARDS.
ONE OR 2 OF THOSE MIGHT ACTUALLY
END UP IN HEART LUNG AND BLOOD
SPACE.
SO BECAUSE IT IS ANTICIPATED
THAT THERE MAY BE MORE
APPLICATIONS THAN THAT THAT ARE
RELEVANT TO HEART LUNG BLOOD
SLEEP COMING INTO THAT ALL OF US
ENVIRONMENT, THE NHLBI ALL OF US
WORKING GROUP PROPOSES THAT
NHLBI FUND UP TO AN ADDITIONAL 2
APPLICATIONS THAT LEVEL IS
CONSISTENT WITH THE ALL OF US
SUPPORTED AWARDS.
SO WHILE YOU'RE SEEING THIS IS
THAT IT'S NOT JUST USING ALL OF
US MONEY, IT'S ACTUALLY USING
ALL OF US MONEY PLUS IT MAY BE
ADDING 1 OR 2 MORE APPLICATIONS
MRI KIGZS THAT COME IN TO THAT
SOLICITATION THAT WOULD USE ALL
OUR MONEY.
WE THINK THIS WILL MAXIMIZE THE
NUMBER OF ICs NOT ONLY THAT
CAN SUPPORT FUNDS ABOUT YOU
HOWEVER, WE USE ALL OUR FUNDS WE
CAN POTENTIALLY CREATE A NICE
CRITICAL MASS ROBUST GROUP AND
BROADLY BASED TRANSNHLBI AND NIH
PROGRAM.
WE ALREADY LOOKED AT THIS AND WE
HAVE COMMITTED TO FUND THIS
PROGRAM, USING ALL OF US MONEY
BUT WE HAVE NOT COMMITTED NHLBI
FUNDS.
SO THAT'S WHY COUNCIL IS LOOKING
AT THIS NOW TO MAKE SURE YOU'RE
IN AGREEMENT WITH THIS.
WE THINK THE RESEARCH SUPPORTED
BY THESE AWARDS WILL HELP
ENHANCE EXPAND NHLBI'S DATA
SCIENCE AND PRECISION HEALTH
PORTFOLIO.
IT WILL PROMOTE WORKFORCE
DEVELOPMENT, HELP PROVIDE THE
OPPORTUNITY TO FUND ADDITIONAL
MERITORIOUS APPLICATIONS AND
HELP CATALYZE EFFORTS AROUND
HEALTH EQUITY AND DEVELOPMENT OF
POPULATION BASE STRATEGIES TO
PREPRENTTREATMENT FROM OUR HEART
LUNG AND BLOOD DISEASES.
SO IT'S A RICH RESOURCE THAT ALL
OF US CREATED FOR US TO TAP INTO
THAT AND BLEND THAT WITH WHAT
WE'RE DOING IN BIODATA CATALYST
SEEMS TO HAVE MERIT.
SO WE WOULD LIKE TO PROPOSE THAT
WE NOT ONLY PARTICIPATE IN THESE
2 INITIATIVES AND HOPEFULLY GET
FUNDS FROM ALL OF US BUT ALSO
USE A MODEL AMOUNT OF NHLBI
FUNDS TO ENHANCE BETTER.
I WILL STOP THERE AND BE HAPPY
TO AGAIN TRY TO ANSWER QUESTIONS
IF THERE ARE ANY.
>>ANY QUESTIONS?
NOT SEEING ANY IN THE CHAT.
>>REMEMBER THERE'S 2 ON THIS 1
AS THERE SO 3825 AND 3826, USING
RO3 MECHANISM OTHERWISE SAME
CONCEPT, SAME APPROACH.
>>JUST ANOTHER MOMENT.
WE'RE ALMOST THERE.
OKAY, LOOKS LIKE WE CAN MOVE ON
TO 3834.
>>THANKS, RUTH, RIGHT.
SO WE'RE ON 3834 AND THIS IS THE
LAST I WILL PRESENT TO YOU FROM
LUNG DIVISION IS LEADING, LAST
BUT CERTAINLY NOT LEAST THIS IS
1 OF OUR FLAGSHIP PROGRAMS IN
THE DIVISION OF LUNG DISEASES.
SO THIS IS LUNG DIVISION
INITIATIVE, NOT TRANSANYTHING
RIGHT NOW, AND IT'S ENTITLED THE
MOLECULARAT LAS PINTAS OF LUNG
DEVELOPMENT PROGRAM, LUNG MAP,
THIS IS USING A U-AMERICAANISM,
A U0124 AND THIS IS A RENEWAL OF
AN EXISTING ONGOING PROGRAM.
SO THE OVERALL GOAL OF THE MAP
IS TO USE CUTTING EDGE
TECHNOLOGY TO BUILD A
COMPREHENSIVE MOLECULAR AND
CELLULAR ATLAS OF THE HUMAN LUNG
TO SERVE AS A REFERENCE TO
BETTER UNDERSTAND BOTH NORMAL
BIOLOGY AND DISEASE
PATHOBIOLOGY.
AND IT'S TO IDENTIFY CRITICAL
CELLULAR COMPONENTS, MOLECULAR
PATHWAYS AND NOVEL THERAPEUTIC
TARGETS IN LUNG DISEASE.
EARLY EFFORTS FROM LUNG MAP HAVE
COMPLETED A MOUSE LUNG ATLAS,
BUT IT'S DEVELOPED NUMEROUS
REAGENTS AND IMPLEMENTED NOVEL
TECHNOLOGY PLATFORMS FOR HUMAN
STUDY AND SO IN THE CURRENT
PHASE, LONG MAP IS BUILDING THE
HUMAN LUNG DEVELOPMENT ATLAS
INCLUDING BOTH NORMAL AND
PEDIATRIC DISEASE LUNGS, WITH
THIS WORK, LUNG MAP HAS BUILT
THAT INFRASTRUCTURE AND THE
PROCESSES TO DEFINE LUNG CELLS
WITH MOLECULAR PROFILES THAT
LINK THAT WITH KNOWLEDGE AND
MORPHOLOGY AND FUNCTION AND NOW
WE'RE READY TO SORT OF TAKE
THOSE APPROACHES AND TRY TO
UNDERSTAND THE PATHOBIOLOGY OF
THE DISEASE.
I DON'T HAVE TO TELL THIS GROUP
AGAIN HOW COMPLICATED THE LUNG
ITSELF IS, THE ORGAN HAS MANY
UNIQUE CELLS, MANY, MANY CELLS,
SOME OF WHICH ARE STILL BEING
UNCOVERED.
SO THE NEXT PHASE OF LUNG MAP IS
TO LEVERAGE ITS EXISTING
INFRASTRUCTURE AND TECHNOLOGY
PLATFORMS, THE STRONG MULTIOMIC
EXPERTISE AND THE DID THEA
INTEGRATION CAPABILITY ASK HAVE
LUNG MAP THEN UTILIZE THE POWER
OF SINGLE CELL AND SPATIAL
OMICs TO IDENTIFY THE
PATHOGENIC MECHANISMS OF LUNG
DISEASE AT A CELLULAR LEVEL SO
WE CAN UNDERSTAND AND INCLUDE
BOTH CELL TYPES, THE STATES OF
THE CRITICAL DISEASE INITIATION
AND PROGRESSION, LOOKING AT THE
MOLECULAR PATHWAYS AGAIN IN
ABNORMAL AND DISEASE CELLS AND
THE POTENTIAL TO TARGET LUNG
DISEASE INTERVENTIONS OR
THERAPIES.
WE BELIEVE THESE HIGH THROUGH
PUT, HIGH RESOLUTION SING CELL
TECHNOLOGIES PROVIDES A GREAT
OPPORTUNITY TO REVEAL THE
HETEROGENERATED AITY IN A NUMBER
OF LUNG DISEASES.
SO THE LUNG MAP RENEWAL WILL BE
AN OPEN COMPETITION BUT CONTINUE
WITH THE CURRENT PROGRAM
STRUCTURE OF A HUMAN TISSUE
CORE, RESEARCH CENTERS AND
RESEARCH DATA COORDINATING
CENTER, A NUMBER OF SCIENTIFIC
FOCUS AREAS THAT WILL GUIDE DATA
PRODUCTION WILL BE HIGHLIGHTED
IN THIS INITIATIVE.
HYPOTHESIS TESTING COMPONENT
WILL BE ALLOWED IN THIS PHASE
WHICH UP TO NOW WE HAVE NOT BEEN
DOING AND THIS WILL LEVERAGE NEW
EXPERTISE IN THE LUNG MAP
PROGRAM TO BRING IN THE
PATHOBIOLOGY COMPONENT.
THE LUNG MAP WILL ALSO MAIN
TAKEN A VERY CLOSE CONNECTION
WITH COLLABORATIONS WITH OTHER
MAP AND ATLAS TYPE PROGRAMS THAT
ARE GOING ON ACROSS NIH, MOST
SPECIFICALLY THE NIH PUB MAP
PROGRAM AND THE NIH HUMAN CELL
ATLAS AND SO DATA SETS, TOOLS
AND TISSUE RESOURCES WILL BE
INTEGRATED INTO THE NHLBI
BIODATA CATALYST ECOSYSTEM AND
AVAILABLE TO OPENLY UTILIZATION
BY THE RESEARCH COMMUNITY.
SO IN SUMMARY LUNG MAP AS BEEN
AN OPEN ACCESS RESOURCE
INTEGRATING MULTISCALE HIGH
CONTENT, HIGH RESOLUTION
INFORMATION TO DEFINE LUNG CELLS
IN GENE EXPRESSION,
PHYSIOLOGICAL STATES, 3D IMAGING
AND LOCATIONS AS WELL AS
DEVELOPMENTAL AND
PATHOBIOLOGICAL TRAJECTORIES,
AND IN THE NEXT PHASE WE PROPOSE
TO APPLY THIS INFRASTRUCTURE TO
TACKLE LUNG DISEASES, BOTH AT
THE PEDIATRIC AND ADULT LEVEL.
SO IT'S BEEN A HIGHLY PRODUCTIVE
PROGRAM.
IT'S STRONGLY SUPPORTED BY THESE
AND AGAIN WE BELIEVE THIS IS
REALLY CUTTING NEW AREAS AND
ADVANCING LUNG DISEASE AND
HOPEFULLY WILL BRING US NOVEL
AND EXCITING NEW DIRECTIONS TO
INTERVENE IN A VARIETY OF
DIFFERENT AREAS.
SO AGAIN I WILL STOP THERE,
DR. SARAH LYNN IN THE LUNG
DIVISION HAS BEEN THE BRAINS
BEHIND THIS PROGRAM AND IS AGAIN
SOMETHING THAT HAS GUIDED THIS
TO ITS CURRENT STATE AND ALSO
AVAILABLE TO ANSWER QUESTIONS.
>>JIM IF I CAN COMMENT.
>>DR. MORISSEY, PLEASE IESHES
DENTIFY YOURSELF.
>>ED, MORISSEY, I'M OBVIOUSLY
CONFLICTED BECAUSE I'M PART OF
LUNG MAP BUT I WANT TO HIGHLIGHT
1 IMPORTANT POINT WHICH HAS BEEN
ALLOWING YOUNG TRAINEES,
ESPECIALLY PHYSICIAN SCIENTISTS
DIRECT ACCESS TO REALLY GETTING
THEIR HANDS WET AND DIRTY WITH
BASIC BIOLOGY AND PHYSICIAN
SCIENTISTS TRAINEES AND FELLOWS
IN MY LAB AND OTHER LABS, YOU
KNOW THEIR EYES JUST SPARKLE BY
THEIR ABILITY TO ACTUALLY WORK
IN THIS GROUP OF INVESTIGATORS
REALLY GETTING INTO THE AREA OF
BASIC SCIENCE.
SO IT'S 1 OF THE OPPORTUNITIES
THAT THE FELLOWS ARE REALLY,
REALLY ENGAGED.
SO IT'S BENEFICIAL TO HELP TRAIN
THIS NEXT GENERATION THAT PEOPLE
THAT ARE GOING TO REPLACE ALL OF
US HERE SOMEDAY AT IN POINT.
JUST WANT TO MAKE THAT COMMENT
BECAUSE I FEEL IT'S REALLY
IMPORTANT.
>>REALLY IMPORTANT, ED, THANK
YOU.
OTHER COMMENTS ON LUNG MAP?
OKAY.
>>I ECHO WHAT ED SAID, IT'S
INCREDIBLE AS A EXPERIENCE AND
RESOURCE.
IS THERE ANY THOUGHT ABOUT
DEVELOPING INITIATIVES SIMILAR
TO WHAT WHAT WE HEARD ABOUT FOR
ALL OF US AND INCENTIVIZING
PARTICULARLY JUNIOR
INVESTIGATORS TO UTILIZE THE
DATA FOR LUNG MAP FOR PROJECTS.
MAYBE THERE IS 1?
>>YEAH, ED MAY BE ABLE TO
COMMENT ON THIS 1 EVEN BETTER
THAN I AM, THAT THERE'S SOME
ASPECTS OF LUNG MAP THAT ARE
BUILT-IN FOR TRAINING AND ACCESS
AND BEING ABLE TO SHOWCASE HOW
TO USE IT, BIODATA CATALYST IS
ANOTHER RESOURCE THAT WE HOPE
WILL ALSO BE ANOTHER TRAINING
GROUND AND PLATFORM TO NOT ONLY
BRING PEOPLE IN TO USE DAT AT IN
THAT ENVIRONMENT BUT ALSO TO
TRAIN PEOPLE ON HOW TO USE THAT
AS WELL SO I THINK THERE ARE A
COUPLE OF WAYS, I'M NOT SURE WE
NEED A SEPARATE INITIATIVE TO DO
THAT BUT AGAIN, MAYBE ED, YOU
COULD HELP WITH THAT.
>>RIGHT?
THE WEBSITE WE LAUNCHED THEIR
NEW WEBSITE A MONTH OR 2 AGO,
IT'S VERY ISHT ACTIVE AND
EVOLVING SITUATION TO TRY TO
ALLOW TO BE ACCESSIBLE TO
EVERYONE, TO THE BROADER
COMMUNITY AT LARGE.
OBVIOUSLY IT'S BIG DATA SET,
REQUIRES A BIT OF UNDERSTANDING
BUT I HOPE WE'RE GOING TO BUILD
OUT TRAINING SESSIONS THAT WILL
BE JUST OUTSIDE OF LUNG MAP THAT
WILL PROVIDE OTHER PEOPLE
[INDISCERNIBLE] AS WELL AND SORT
OF TEASE THE AMOUNT OF DATA ON
THERE BECAUSE IT'S QUITE
IMPRESSIVE OVER THE NEXT YEAR OR
2, CAN YOU SEE THIS AS WELL.
>>YEAH,--YEAH, GO AHEAD GARY.
>>YEAH, NO, JUST TO--IT'S A
GREAT DISCUSSION AND YOU KNOW WE
HAVE TO VOTE BUT THIS IS AN AREA
WHERE WE LOOK FORWARD TO YOUR
INPUT AND IDEAS ABOUT HOW WE CAN
ENGAGE NOT ONLY THOSE WHO ARE
KIND OF BUILDING IT, WE HAD THE
SAME ISSUE WITH TOP MED PDC BUT
THEN PART OF THE INTENTION IS TO
DEMOCRATIZE IT, DISSEMINATE IT,
AND MAKE IT MORE ACCESSIBLE, I
ADEGREE WITH YOU AND WE WANT THE
NEXT GENERATION TO DRIVE IT AND
GET IS TO THE PLAY SPACE.
SO AGAIN HAVING THE ONRAMP, EVEN
IF THERE IS A TRAINING
COMPONENT, WE WOULD LOVE TO HEAR
YOUR IDEAS BECAUSE IT'S
HAPPENING IN BDC AS WELL, SO WE
HAVE TO GET PARTICULAR AT FROM
THOSE WHO ARE CREATORS TO THOSE
WHO JUST WANT TO ENGAGE AND
COMPARE.
SO, LOOK FORWARD TO THAT,
INCLUDING, YOU KNOW, WE HAVE TO
THINK ABOUT MECHANISMS EITHER
BUILT INTO THE BUILDING OR
DISSEMINATING SO LOOK FORWARD TO
COUNCIL'S INPUT.
>>OKAY, THANK YOU ANY OTHER
COMMENTS ON LUNG MAP.
GO AHEAD AND FINISH UP THE
VOTING OR HAS THAT BEEN DONE?
>>WE'RE ALMOST DONE, JUST
WAITING ON 1 OR 2 MORE VOTES.
IF YOU COULD PATIENT PLEASE,
THANK YOU.
>>AS YOU FINISH UP THERE, THAT
CONCLUDES THE PRESENTATION OF
THE INITIATIVES THAT THE LUNG'S
DIVISION'S LEADING AND I THINK
WE WILL TURN IT OVER TO YOU
[INDISCERNIBLE].
YEAH, SO IT'S GOING TO DR. P A
NEPINTO AS SOON AS YOU FINISH
VOTING ON THIS.
>>THANK YOU WE WILL PRESENT 3
INITIATIVES TODAY, 2 OF THEM ARE
COMPANION OR PAIRED, THANK YOU
TO THE STAFF WHO WORKED ON THESE
INCLUDING DVD R, AND THE
DOCTORS.
THE FIRST INITIATIVE IS IDEAS
2809, DATA MANAGEMENT AND
COORDINATING CENTER FOR
DIAGNOSTIC CENTERS OF
EXCELLENCE, UTC CLINICAL TRIAL
NOT ALLOWED.
THIS IS A REQUEST TO RENEW NHLBI
SECONDARY PARTICIPATION TO THE
PHASE 2--SORRY, PHASE 3 OF
UNDIAGNOSED DISEASE NETWORKS OR
UDN, A TRANSNIH INITIATIVE WITH
THE LEADING IC BEING NINDS.
THE OBJECTIVE OF THIS SPACE OF
RENEWAL IS TO HAVE IT EVOLVE
INTO A LARGER SUSTAINED NETWORK
OF CLINICAL SITES THAT WILL
INCREASE IMPACT ON THE COMMUNITY
AND THE HEALTH KAY SYSTEM
THROUGH TRANSLATIONAL RESEARCH
TEEJIC PARTNERSHIPS WITH PATIENT
ADVOCACY GROUPS WITH TAKE
STOLEDDERS WITH HEALTHCARE
PAYERS AND INCREASE DIVERSITY
EEQUITY AND INCLUSION, BY
IMPLEMENTING STRATEGIES TO
RECRUIT PARTICIPANTS FROM
SOCIOECONOMIC LOAMACYY DIVERSE
BACKGROUNDS AND CLINICAL SITES
THAT SERVE DIVERSE POPULATIONS.
IT AIMS TO ACHIEVE THESE
OBJECTIVES BY SUPPORTING A DATA
MANAGEMENT CENTER, A DMCC, THAT
WILL PROVIDE INFRASTRUCTURE,
DATA MANAGEMENT AND CLINICAL
RESEARCH SUPPORT FOR NEW NETWORK
OF CLINICAL SITES TO PROSLIDE
DIAGNOSTIC SERVICES FOR PATIENTS
WITH DIFFICULT TO DIAGNOSE
DISEASES.
THE NEW NETWORK IS INTENDED TO
SUSTAIN SOME OF THE ACTIVITIES
CURRENTLY PERFORMED BY THE
UPDIAGNOSED DISEASES NETWORK, AN
NIH COMMON FUND PROGRAM THAT WAS
ESTABLISHED IN 2013.
THE DMCC WILL COORDINATE THE NEW
NETWORK IN 2023, AS DIAGNOSTIC
CENTERS OF EXCELLENCE THROUGH A
RELATED RESOURCE ACCESS
MECHANISM, XL1.
THE DMCC WILL SUPPORT THESE
DIAGNOSTIC CENTERS AND
COORDINATE TRANSNETWORK
ACTIVITIES, WITH SERVICES
MANAGED ACROSS 3 CORES.
ONE, ADMINISTRATIVE CORE, 2 DATA
MANAGEMENT CORE, AND 3 CLINICAL
RESEARCH CORE.
THE UNDIAGNOSED DISEASES NETWORK
USES A TEAM SCIENCE APPROACH CAN
ENCLUEDING A CLINICAL
EVALUATION, DATA SHARING AND
COLLABORATION ACROSS SITES,
ADVANCED DIAGNOSTIC TOOLS SUCH
AS FULL GENOME OR EXOHM
SEQUENCING AND DRAMATIC
EXPERTISE, RNASEQ, GENE STUDIES
AND METRICS TAB O LOAMICS.
SINCE 2013 GREATER THAN 5800
APPLICATIONS HAVE BEEN RECEIVED,
40% ACCEPTED BY THE NETWORK,
WHOLE OF GENOME OR WHOLE EXOHM
SEQUENCING WAS CONDUCTED IN OVER
90% OF PARTICIPANTS WHO WERE
ACCEPTED INTO THE NETWORK, OF
THOSE EVALUATED WHICH IS
APPROXIMATELY 1800, 30% OF THEM
RECEIVED A DIAGNOSIS.
THE UDN AS ENABLED THE DISCOVERY
OF OVER 100 NOVEL DECEASE
ASSOCIATED GENES OR VARIANTS,
DISEASE MECHANISMS OR NEW
SYNDROMES AND IMPORTANTLY 70% OF
PATIENTS ENROLLED IN THE NETWORK
PRESENT UPON WITH AT LEAST 1
HEART, LUNG, BLOOD SEEP
ABNORMALITY MAKING THE NHLBI 1
OF THE TOP ICs BENEFITING FROM
THE PROGRAM.
DO ANY MEMBERS HAVE ANY
QUESTIONS OR WISH TO DISCUSS
THIS?
>>MY QUESTION IS ABOUT HEALTH
DISPARITIES POPULATION AND ARE A
SIGNIFICANT NUMBER OF THE
CLINICAL PARTNERS TARGETING
RURAL POPULATIONS, UNDERSERVED
POPULATIONS, POPULATIONS THAT
ARE SERVING PRIMARILY BY CANNED
WHAT INDIVIDUALS?
>>SO THANK YOU FOR THE
QUESTION, SO THE SCIENCE WILL BE
IDENTIFIED THROUGH A NEW
MECHANISM, XL1 SO THEY'RE NOT
YET IDENTIFIED, BUT I WOULD
EXPECT GIVEN THAT 1 OF THE MAIN
OBJECTIVES OF THE DE& I AND
THEY WILL BE REPRESENTED IN THAT
AND I DON'T KNOW IF
DR. ALACAZAAR HAS ANY OTHER
DETAILED RESPONSE?
I THINK SHE'S ON THE LINE?
>>WE WILL BE ANOTHER FOA FOR
[INDISCERNIBLE] AND CLINICAL
[INDISCERNIBLE] WILL BE SELECTED
FOR THE [INODD AUDIBLE ]
>>GREAT, ANY OTHER QUESTIONS ON
THIS?
>>NOT SEEING ANY.
JUST A REMINDER FOLKS, ANNOUNCE
YOURSELF WHEN YOU START TO SPEAK
SO OUR VIRTUAL AUDIENCE CAN
FOLLOW ALONG.
>>I WAS JUST GOING TO MAKE A
COMMENT AS WELL.
>>YES, AND YOU ARE?
>>JENNIFER DEVOE.
KIND OF BUILDING ON WHAT
DR. FRETZ ASKED AND WHEN WE
TALKED ABOUT EARLIER, I
THINK--THERE ARE CERTAINLY
EXCEPTIONS BUT I KNOW THAT DATA
COORDINATING CENTERS TEND TO BE
THE MOST ADVANCED INSTITUTIONS
THAT DON'T TRADITIONALLY HAVE
UNDERREPRESENTATION OF OR
REPRESENTATIONS FROM MINORITIES
OR RURAL AREAS THAT ARE HARD TO
REACH.
SO I WOULD SUGGEST FOR FUTURE
GIVING THAT I WILL BE ROTATING
OFF SOONER RATHER THAN LATER TO
KEEP IN MIND DIFFERENT PARADIGMS
AND DIFFERENT MODELS, CAN YOU
HAVE LIKE A COORDINATING CENTER,
ANOTHER COORDINATING CENTER, CAN
YOU HAVE A HUB AND SPOKE MODEL
WHERE ALL THE RESOURCES ARE NOT
GOING TO 1 PLACE AND BARELY
TRICKLE DOWN TO THE COMMUNITIES
THAT THEY SERVE AND SO JUST--I
KNOW THAT IT'S EASIER JUST TO
THINK OF LET'S HAVE 1 CENTER ASK
HAVE THAT CENTER GET A HUGE
AMOUNT OF MONEY BUT AS WE TALK
ABOUT MENTORING, WE NEED TO TALK
ABOUT SCIENTISTS MENTORING
SCIENTISTS BUT INSTITUTIONS
MENTORING INSTITUTIONS AND
BUILDING THOSE MODELS INTO THE
FOAs BECAUSE OTHERWISE THESE
LARGE DATA COORDINATING CENTERS
GO TO THE USUAL SUSPECTS, THEY
ALSO DO, TELL BE GREAT TO SEE A
MAP OF WHERE THEY ARE, MAYBE YOU
CAN PRESENT THAT AT A LATER
SESSION AS WELL, BUT I THINK
THAT ALL OF THESE MECHANISMS
NEED TO BE REVIEWED AND WE NEED
TO JUST THINK CREATIVELY.
IT'S MORE DIFFICULT, IT'S MORE
COMPLEX, SOME PLACES ARE MORE OR
LESS READY BUT JUST THINKING
ABOUT HOW WE CAN BUILD IN SOME
OF THOSE MENTORSHIP MODELS TO
EVERY SINGLE OPPORTUNITY.
NTHANK YOU DR. DEVOE.
>>YEAH, I APPRECIATE THAT
COMMENT AND IT RESONATES.
THIS IS SOMETHING WE TO BUILD IN
COLLECTIVELY AS A COMMUNITY
SINCE FOLKS AROUND THE TABLE ARE
VERMEN INFECTED VIEWERS AS WELL
AS RECIPIENTS AND SOME ARE AT
THOSE CENTERS AND JUST
PARENTHETICALLY, I WILL NOTE THE
NHLBI'S PLAYED KIND OF A
LEADERSHIP ROLE IN RECOVERING,
LONG COVID AND BUILDING THAT
NETWORK VERY QUICKLY.
ONE ELEMENT OF LEVERAGE IN THE
OTHER TRANSACTION AUTHORITY,
BUILDING BASICALLY UPON NETWORKS
WAS THE NETWORK OF THE IDEA
STATES AND I MIGHT SAY THAT THAT
NETWORK OF CLINICAL STUDY SITES
IS OUT PERFORMING SOME OF THE 1S
ON THE COASTS, AND ENGAGING
POPULATIONS WE WOULD NOT
ORDINARILY HAVE HAD, SO I TAKE
YOUR POINT AND I THINK THAT'S
CRITICAL.
YOU MAY ALSO BE AWARE THAT AS
PART OF THE COMMUNITY ENGAGED
RESEARCH PLATFORM, WE'RE LOOKING
FOR OPPORTUNITIES FOR COMMUNITY
EMBEDDED RESEARCH NETWORKS, AND
AGAIN, THAT MAY BE SOME
UNCONVENTIONAL ENTITIES AND
NETWORKS BUT I AGREE WITH YOU, I
THINK WE HAVE TO PROACTIVE IN
BUILDING THAT CAPABILITY.
THANK YOU FOR THAT.
>>YEAH.
>>YEAH, I THINK A FOLLOW ON.
WE'RE IN A STAGE NOW WHERE WE
HAVE A LARGE ACADEMIC CENTER
THAT TENDS TO BE THE
COORDINATING AND THEN STUFF
TRICKLES DOWN THROUGH THE
COMMUNITY SO WE THEED TO DO THIS
EVEN FURTHER AND IT'S AN EQUAL
PARTNERSHIP.
THE GOOD NEWS IS THAT THE
PROGRAM OFFICER WHO'S
REPRESENTING NHLBI ON THIS BIG
EFFORT HAS HEARD EVERYTHING THAT
WE SAID, SO I KNOW SHE'S GOING
TO BE TAKING THAT TO HEART AND
USING HER INFLUENCES AS BEST SHE
CAN.
ARE WE ALMOST DONE WITH THIS 1?
>>WE'RE READY TO MOVE ON.
>>THANK YOU.
OUR NEXT INITIATIVES THAT ARE
PAIRED, IDSNUMBER 2821 AND 3846,
THE BLOOD AND MARROW TRANSPLANT
CLINICAL TRIALS DATA
COORDINATING CENTER, U24 RENEWAL
AND THE BLOOD AND MARROW
TRANSPLANT CLINICAL TRIALS
CLINICAL CENTERS UH1.
THIS IS A COMPETITIVE RENEWAL OF
THE BLOOD AND MARROW TRANSPLANT
CLINICAL TRIALS NETWORK, NIH'S
IMPROVE OUTCOME FOR CHILDREN AND
ADULTS WITH BLOOD STEM CELL
THERAPIES.
THE PRIMARY OBJECTIVE IS TO
EXTEND STEM CELL TRANSPLANTATION
AND NOVEL AND CELL THERAPIES IF
ARE ALL PATIENTS ABOUT YOU
PARTICULARLY FOR PATIENTS WITH
RARE ACQUIRED AND
CONGENERATEDETTAL NONMA LIGNABT
BLOOD DISEASES, NONMALIGNANT
BLOOD DISEASES ARE RARE AND
INVOLVE CELL STEM CELL
TRANSPLANTATION, IN ADDITION,
GENETIC AUTOLO GUS CELLS
DELIVERED IN THE PLATFORM IS
ALSO AN OPTION.
A NETWORK OF PROGRAMS IS NEEDED
TO NEEDED TO CONDUCT MULTISITE
TRIALS WITH PATIENTS WITH RARE
DISEASES AND INCORPORATE USING
NEW APPROACHES IN BLOOD STEM
CELL TRANSPLANTATION.
THE BMCTN HAS PROVEN TO BE THIS
PROGRAM.
THE BMCTN IS A HIGHLY EFFECTIVE
PROGRAM CONDUCTING ALOE
GENERATED AIC APPROACHES FOR
PAIBTS WITH THESE DISEASES, AND
EVALUATING INNOVATIVE ADOPTIVE
CELL THERAPIES SUCH AS T-CELLS
FOR THE RESERVOIR AND
GENETICALLY MODIFIED AH
TOLL-LIKE RECEPTOR GUS CELLS,
AND WE KNOW FROM THE RECEIPT
SCIENTIFIC WORKSHOPS FOR
NONMALIGNANT BLOOD DISEASES THAT
THERE IS STILL HOWEVER, MUCH TO
BE DONE IN THE FUTURE.
IN THIS PROPOSED RENEWAL, THE
BMCTN WILL CONTINUE TO ADADVANCE
TRANSPLANTATION AND ADOPTIVE
CELL THERAPIES FOR PATIENTS
ACROSS THE LIFE SPAN WHILE
ADHERING TO SEVERAL OVERARCHING
TENANTS RECOMMENDED DURING THE
LAST YEAR'S B-COUNCIL MEETING ON
CLINICAL TRIALS NAMELY
DIVERSITY, EQUITY AND INCLUSION,
TRAINING THE NEXT GENERATION AND
COLLABORATION.
ADDITIONALLY FOR THE RENEWAL IS
A REQUIREMENT FOR BMCTN TO BUILD
A SHAREABLE, PROSPECTIVE
BIOSPECIMEN LINKED TO PATIENTS
WITH NONMALIGNANT BLOOD
DISEASES.
IN SUMMARY THIS A COMPETITIVE
RENEWAL OF A NETWORK THAT'S BEEN
HIGHLY PRODUCTIVE AND EFFECTIVE
WHILE INCORPORATING NEW FUTURES
AND TENANTS TO HELP INCREASE
INVESTIGATE POOL, BOTH VALUABLE
AND SHAREABLE BIOSPECIMEN
COLLECTION WHILE ADDRESSING THE
NEEDS OF PATIENTS WITH
NONMALIGNANT BLOOD DISEASES,
SEEKING CURATIVE TREATMENTS.
DO ANY MEMBERS HAVE ANY
QUESTIONS OR WISH TO DISCUSS THE
INITIATIVE?
>>SORRY.
>>DR. NARLA.
>>VERY SLOW LEARNER, SORRY.
THIS IS VERY IMPORTANT
[INAUDIBLE ] LESS MORE
COMPLICATED.
>>THANK YOU DR. NARLA.
ANY OTHER COMMENTS OR
DISCUSSION?
I'M NOT SEEING ANY.
>>REMEMBER TO VOTE ON THESE AS
DISTINCT 2821 AND 3846.
[MUSIC PLAYING ]
>>DID EVERYBODY SET THEIR ALARM
OR?
SERENDIPISOUS, EVERYBODY'S PHONE
IS RINGING.
CAN YOU PLEASE PUT THEM ON
SILENT.
>>HOW ARE WE DOING?
>>WE ARE MAKING GOOD PROGRESS
BUT WE HAVE A FEW VOTES TO COME
IN YET, PLEASE.
>>ALL RIGHT.
WE CAN GO AHEAD AND MOVE ON.
>>OKAY, WE WILL GO TO THE
CENTER FOR IMPLEMENTATION
SCIENCE, DR. METZA?
>>THANK YOU DR. MOEN, GEORGE
MENZA, FROM THE TRUSTEES FOR
IMPLEMENTATION SCIENCE, OR
CITRIS, AND WE HAVE 2 CONCEPTS,
I'M RESENTING THEM FROM CITRIS,
WE REPRESENT NHLBI WIDE EFFORT
RESEARCH PROGRAM.
AND THE WORK WAS DONE BY STAFF
AND OF COURSE IN ALL THE
DIVISIONS, I WANT TO
PARTICULARLY THANK DR. ELI,A S
WHO IS THE LEAD AUTHOR AS WELL
AS DOMAIN EXPERTS AND DATA
SCIENTISTS FROM ACROSS ALL THE
DIVISIONS.
BOTH CONCEPTS ARE REQUESTED FOR
NHLBI TO JOIN AND SUPPORT A
MAJOR NIH COMMON FUND PROGRAM.
THIS IS THE PROGRAM ON
HARNESSING DATA SCIENCE FOR
HEALTH DISCOVERY AND INNOVATION
IN AFRICA.
WE COMMONLY REFER TO IT AS DSI
AFRICA.
EACH OF THE CONCEPTS REQUIRES A
SEPARATE VOTE BUT BECAUSE THEY
ARE BOTH RELATED TO THE DSI
AFRICA PROGRAM, I FIRST PROVIDE
A BIT OF A BACK GROWBD ON DSI
AFRICA.
JUST FOR CONTEXT AND THEN TELL
YOU ABOUT THE 2 2 CONCEPTS AND
THEN ASK FOR YOUR VOTE.
FOR BACKGROUND, THIS WAS JUST
LAST YEAR THE NIH COMMON FUND
ISSUED 19 AWARDS UNDER THE DSI
AFRICA PROGRAM.
THEY'RE ALL DESIGNED TO HELP
ADVANCE, HEALTH DISCOVERIES AND
ALSO CATALYZE INNOVATIONS IN
HEALTHCARE, PUBLIC HEALTH AND
OVERALL BIOMEDICAL RESEARCH
ENTERPRISE IN AFRICA.
SPECIFICALLY THROUGH THE
APPLICATIONS OF DATA SCIENCE
APPLICATIONS.
THE CONSORTIUM NOW INCLUDES 1 A
DATA SCIENCE PLATFORM IN A
COORDINATING CENTER, THERE ARE 7
RELATED RESEARCH HUBS, THERE ARE
7 DATA SCIENCE RESEARCH TRAINING
PROGRAMS AND IMPORTANTLY 4
PROGRAMS THAT ADDRESS THE
ETHICAL, LEGAL, AND SOCIAL
EMPLICATIONS OF DATA SCIENCE
RESEARCH.
THE PRIMARY OBJECTIVE OF THIS
PROGRAM IS REALLY TO LEVERAGE
DATA SCIENCE TECHNOLOGIES AND
PRIOR NIH INVESTMENTS LIKE THE
[INDISCERNIBLE] AFRICA PROGRAM
SO THAT THESE INVESTIGATORS ON
THE CONINENT CAN DEVELOP
PROGRAMS TO THE CONTINENT'S
PRESSING HEGHT PROBLEMS WHICH
MANY ARE IN HYPERTENSION, HEART
DISEASE, HEART FAILURE, ASTHMA,
OTHER CHRONIC LUNG DISEASES AND
SICKLE CELL DISEASE.
THE 2 CONCEPTS BEFORE YOU TODAY
BUILD ON THIS INFRASTRUCTURE BY
DOING 2 THINGS.
ONE SUPPORTING DISCREET RESEARCH
PROJECTS, THAT'S THE CONCEPT
2817, USING THE UO1 MECHANISM
AND THE SECOND IS TO SUPPORT
EDUCATION RESEARCH ACTIVITIES
USING THE UE5 MECHANISM ISSUES
THAT'S CONCEPT 2318.
SO I TELL YOU FIRST ABOUT 2817.
THIS IS THE PARTNERSHIP FOR
DISCREET INNOVATION RESEARCH
PROJECTS AND THAT'S IN THE UO1.
THE OBJECTIVE IS TO SUPPORT
DISCREET RESEARCH PROJECTS LED
BY INVESTIGATORS IN AFRICA TO
EXPAND THE CURRENT
INFRASTRUCTURE FOR THE DSI
AFRICA CONSORTIUM.
THE RESEARCH FUNDED THROUGH THIS
FOA WILL SERVE TO ADVANCE IT,
OVERALL GOALS OF DSI AFRICA BUT
IMPORTANTLY THEY ALSO AIM TO
ENHANCE THE CAREER PATHWAY.
I THINK DR. THOMAS WAS VERY
PLEASED TO HEAR THAT I DIDN'T
SAY PIPELINE.
WE LEARN VERY QUICKLY AND
HOPEFULLY, IN THE RENEWAL, MAKE
SURE WE EMPHASIZE PATHWAYS TO
PROMOTE RETENTION ON THE
CONTINENT.
THE HEALTH DATA SCIENTISTS IN
AFFRIC WHO WERE SUPPORTED TO
DEVOTE NEW AND ESPECIALLY WORK
WITH EARLY STAGE INVESTIGATORS.
SO THAT WAS CONCEPT 2817.
2818 IS THE DSI AFRICA NIH
RESEARCH EDUCATION PROGRAM USING
THE UE5 MECHANISMS.
THE OVERARCHING GOAL OF THIS
SECOND CONCEPT IS TO SUPPORT
RESEARCH EDUCATION ACTIVITIES IN
THE MISSION AREAS OF NHLBI.
IN PARTICULAR, WE'RE VERY
INTERESTED IN EDUCATIONAL
ACTIVITIES, THAT COMPLEMENT
AND/OR ENHANCE THE TRAINING OF
THE WORKFORCE WITH THE
BIOMEDICAL, BEHAVIORIAL AND
CLINICAL RESEARCH NEEDS ON THE
DSI AFRICA PROGRAM.
TO ACCOMPLISH THE STANDARD
OBJECTIVE THIS FUND OPPORTUNITY
WILL SUPPORT CREATIVE
EDUCATIONAL ACTIVITIES FOR THE
PRIMARY FOCUS ON COURSES FOR
SKILLS, DEVELOPMENT, THAT REALLY
FILL A GAP OR A NEED WITHIN THE
DSI AFRICA CONSORTIUM AND AT THE
SAME TIME AS ADVANCING THE
OVERALL GOAL OF THE PROGRAM.
THE ARK DITIONAL FUNDS THAT
NHLBI PROVIDE WERE LEVERAGED
THIS UNIQUE INYAISHATIVE TO
DRIVE AND EXPAND HEART LUNG
BLOOD AND DATA RESEARCH SCIENCE
CAPACITY BUILDING ON THE AFRICA
KNOW CONTINENT AS A STRATEGIC
PRIORITY FOR THE INSTITUTE.
WE REALLY SEE A UNIQUE
OPPORTUNITY FOR THESE 2 PROGRAMS
TO LEVERAGE INVESTMENT WE'VE
MADE IN DATA SCIENCE FOR
EXAMPLE, THROUGH THE DATA
CATALYST TO SUPPORT DATA SCIENCE
ACTIVITIES IN AFRICA AND RELATED
TRAIPING AND CAREER DEVELOPMENT.
I WILL STOP HERE AND SEE IF YOU
HAVE ANY QUESTIONS ISSUES
COMMENTS OR SUGGESTIONS FOR US
FOR THESE 2 PROGRAMS.
>>I HAVE'S QUESTION.
>>PLEASE.
>>SO DR. --WHO'S SPEAKING.
>>THIS IS MANDY FRETZ SPEAKING,
IT SEEMED CLEAR THAT SUCCESS FOR
RETENTION OF RESEARCHERS,
TRAINING AND INCREASING CAPACITY
BUT I WONDERING ABOUT THE
SUSTAINABILITY OF THE
PARTNERSHIPS BETWEEN THE
ACADEMIC AND NONACADEMIC
INSTITUTIONS, IT SEEMS LIKE IT
WOULD BE ADVANTAGEOUS IF THESE
WERE A SUSTAINABLE PARTNERSHIP
IF WOULD GO BEYOND THE FUNDING
INYAISHATIVE.
>>IT'S AN EXCELLENT QUESTION
AND FOR ALL OF OUR PROGRAMS
ESPECIALLY FOR THE
IMPLEMENTATION SCIENCE THAT, IS
A KEY OUTCOME.
WE'RE VERY FORTUNATE WE NEAR
PARTNERSHIP WITH FOGARTY, WE
HAVE EXPERIENCE IN THIS AREA,
BUILDING SUSTAINABILITY FOR THE
LONG-TERM, 1 OF THE THINGS THAT
WE HOPE WOULD HELP IS ALSO THE
EMPHASIS ON STRATEGIC
PARTNERSHIPS BEYOND THE
CONSORTIUM, TYPICALLY INVOLVED
MINISTRYINGS OF HEALTH AND ALSO
PRACTICE, SO YES, SUSTAIN NLT IS
A MAJOR PART OF THIS, THANK YOU.
ALL RIGHT, IF YOU COULD GO AHEAD
AND PLEASE REMEMBER TO VOTE FOR
2817 AND 2818.
>>JUST ANOTHER MOMENT OR 2,
PLEASE.
WE CAN GO AHEAD AND MOVE ON.
>>ALL RIGHT.
I WILL TURN IT OVER TO DR. MOEN.
>>ALL RIGHT.
SO I'M GOING TO TURN IT BACK TO
DAVID.
BECAUSE HE'S GOING TO HANDLE THE
DR1S AND THE DCDS.
>>HI, GAIN THIS IS DAVID GOFF,
CARDIOVASCULAR SCIENCES AND IT'S
MY PLEASURE TO PRESENT 2
INITIATIVES TO YOU TODAY.
ONE FROM DERA AND 1 FROM DCBS,
ABOUT YOU IN REALITY, THEY'RE
BOTH TRANSNHLBS AND TRANSNIH IN
NATURE.
THE FIRST IS NUMBER 3823.
YES.
IT'S THE RENEWAL OF NHLBI
SECONDARY PARTICIPATION AND
ND22004 INNOVATIONS FOR HEALTHY
LIVING, SBIR, RFA, R43, R44
MECHANISMS, CLINICAL TRIAL
OPTION AND THE LEAD OFF OF THIS
DR. DAVIS FROM [INDISCERNIBLE].
THE GOAL OF THE SECONDARY SIGN
ON IS TO ARE RENEW OUR
PARTICIPATION IN THE NATIONAL
MINORITY AND HEALTH DISPARITIES
FOR THE HEALTHY LIVING RFA IS TO
SUPPORT THE DEVELOPMENT
OPTIMIZATION, ADOPTION AND
REPURPOSING OF NEW DEVICES,
DIGITAL HEALTH AND DIAGNOSTIC
TOOLS BY SMALL BUSINESSES TO
BETTER MEET THE SPECIAL NEEDS OF
PATIENTS FROM UNDERSERVED
POPULATIONS WHO ARE LIVING WITH
HEART AND LUNG, BLOOD, SLEEP
CONDITIONS.
ADVANCES IN DIGITAL HEALTH AND
POINT OF MEDICINE AND CARE
TECHNOLOGIES HAVE IMPROVED THE
ABILITY OF PATIENTS TO MANAGE
THEIR HEALTH BUT SEVERAL ISSUES
PREVENT THESE TECHNOLOGIES FROM
BEING WIDELY USED AND IN
UNDERSERVED POPULATIONS.
IN 2021, NHLBI SIGNED ON AS A
SECONDARY PARTICIPATING
INSTITUTE IN THIS RFA TO
ENCOURAGE THE DEVELOPMENT OF
DEVICES AND TECHNOLOGIES TO
IMPROVE THE DIAGNOSIS AND
MANAGEMENT OF HEART LUNG BLOOD
AND SLEEP CONDITIONS IN THESE
POPULATIONS.
AND WHILE THE SMALL BUSINESS
GRANTS PROGRAM HAS FUNDED THE
DEVELOPMENT OF NEW DIAGNOSTIC
AND MONITORING DEVICES IN HOME
SETTINGS, ONLY 4% OF SMALL
BUSINESS AWARDS FROM FISCAL YEAR
17-72 HAVE SUPPORTED DEVICES
THAT SPECIFICALLY TARGET
UNDERSERVED POPULATIONS.
SO WE ENCOURAGE COUNCIL TO
CONSIDER THE VALUE OF OUR
CONTINUED PARTICIPATION AND
INNOVATIONS FOR HEALTHY LIVING,
SBIR RFA TO INSURE THAT NHLBI
SMALL BUSINESS PROGRAMS FUNDING
TECHNOLOGIES THAT WE SERVE
HISTORICALLY MARGINALIZED AND
UNDERSERVED POPULATIONS AND
IMPROVE THEIR QUALITY OF LIFE.
HAPPY TO ANSWER QUESTIONS OR
REFER THEM TO DR. DAVIS.
IF THERE AREN'T ANY QUESTIONS OR
COMMENTS, WE CAN START RATING
THIS CONCEPT.
>>I'M NOT SEEING ANY QUESTIONS,
DAVID.
>>JUST TO REMIND THIS, IS 3823.
>>WE CAN MOVE ON TO 3822.
>>ALL RIGHT, THANK YOU.
THIS IS RENEWAL OF THE HISPANIC
COMMUNITY HEALTH STUDY, STUDY OF
LATINOS THROUGH A CONTRACT
MECHANISM NO1 AND THE WELLED
AUTHOR FOR THIS IS JOHN KUNTZ
FROM THE DIVISION OF
CARDIOVASCULAR SCIENCES AND
CUTTING TO THE CHASE THIS IS
REALLY KIND OF OUR LANDMARK
COHORT STUDY FOR HISPANIC HEALTH
FOR THE COUNTRY.
SO ALTHOUGH NHLBI LEADS IT, IT
PROVIDES A PLATFORM FOR TRANSNIH
ACTIVITIES.
THIS INITIATIVE CALLS FOR
CONTINUATION OF SUPPORT OF
INFRASTRUCTURE FOR THIS COHORT,
INCLUDES OVER 15,000 SURVIVING
PARTICIPANTS WHO SELF-IDENTIFY
AS HISPANIC OR LATINO, PERFORM
MAJOR METROPOLITAN AREAS ACROSS
THE U.S. IN ORDER TO INCLUDE
INDIVIDUALS MEXICAN, PUERTO
RICAN, DOMINICAN, CUBAN, AND
SOUTH AND CENTRAL AMERICAN
ORIGINS.
RETENTION HAS BEEN EXCELLENT
WITH 82% OF THE PARTICIPANTS
CONTACTED DURING THE LAST 3
YEARS, PRODUCTIVITY HAS ALSO
BEEN EXCELLENT WITH OVER 400
PUBLICATIONS LEADING TO ALMOST
5000 CITATIONS INCLUDING AUTHORS
FROM 490 INSTITUTIONS AND 36
DIFFERENT COUNTRIES.
AND IN THE PAST 4 YEARS, SINCE
TRANSITIONING TO THE PLATFORM
MODEL OF THE COHORT'S SUPPORT,
THERE ARE 17 ANCILLARY STUDIES
THAT HAVE BEEN INTEGRATED INTO
THE STUDIES ONGOING THIRD EXAM
THROUGH INVESTIGATOR INITIATED
APPLICATIONS.
SO RENEWAL OF SUPPORT WILL
PRESERVE OUR INVESTMENT IN THE
LARGEST AND MOST COMPREHENSIVE
STUDY OF HISPANIC AND LATINO
HEALTH IN THE U.S. BY
IDENTIFYING EVENTS IN THE 6
HERITAGE GROUPS LEVERAGING THE
STUDIES DATA AND BIOLOGICAL
SPECIMENS FOR HEART LUNG BLOOD
AND SLEEP RESEARCH AND ALLOW THE
STUDY TO CONTINUE TO SERVE AS A
PLATFORM FOR INVESTIGATOR
INITIATED ANSWERED STUDIES.
FOLLOWING DISCUSSION WE ADDED A
MODEST AMOUNT OF FUNDS TO ENABLE
GEOCODING OF RESIDENTIAL
DESCREASESS TO SUPPORT
ADDITIONAL DOMAINS RESEARCH,
INCLUDING THIS EXAMPLE FOR THE
SOCIAL DETERMINANTS OF HEALTH
VARIABLES AND CLIMATE HEALTH
EXPOSURES.
AT THIS POINT I WILL BE HAPPY TO
ENTERTAIN QUESTIONS OR REFER TO
JOHN KUNTZ, OR WE CAN GO TO
RATING THIS CONCEPT.
>>ANYBODY HAVE ANY QUESTIONSER
COMMENTS?
--QUESTIONS, COMMENTS?
APPARENTLY NOT.
>>ALL RIGHT.
AND TO REMIND THIS IS CONCEMENT
3822.
>>WE'RE ALMOST THERE.
>>ALL VOTES HAVE BEEN RECEIVED.
THAT'S THE END OF OUR
INITIATIVE.
BACK TO YOU.
>>ALL VOTES HAVE BEEN RECEIVED.
SO WE'RE AT A CLOSE ON THE
VOTING.
>>THANK YOU.
SORRY.
I'M PROBABLY LOSING MY HEARING.
JUST ANOTHER ONE OF THOSE THINGS
THAT HAPPENS.
OKAY.
SO THANKS, EVERYBODY, FOR
VOTING.
AND THANKS FOR YOUR
PARTICIPATION.
WE REALLY VALUE THE COMMENTS I
HOPE YOU PUT IN SINCE THERE
WASN'T A LOT OF DISCUSSION ABOUT
INITIATIVES, WELL, CONCEPTS.
I DO APPRECIATE EVERYBODY'S
COMMENTS ABOUT THE CONCEPTS THAT
WERE MADE.
DR. GIBBONS, THIS BRINGS US TO
THE END OF WHAT WE PLANNED
TODAY.
WONDERING IF YOU WANT TO OPEN
THINGS UP FOR DISCUSSION BEFORE
WE ADJOURN THE MEETING, IF
THERE'S ANYTHING YOU WANT TO
BRING TO THE PEOPLE'S ATTENTION?
>>NO, JUST A NOTE OF
APPRECIATION AGAIN FOR YOUR
PROVIDING PRECIOUS TIME,
COLLECTIVELY.
REALLY APPRECIATE THE FEEDBACK
AND DISCUSSION WE'VE HAD.
THIS IS SOMETHING THAT SOMETIMES
CAN GET A LITTLE BIT CHALLENGING
IN A VIRTUAL SETTING, SO I
REALLY APPRECIATE YOU GUYS
LEANING INTO THAT.
IF THERE AREN'T FURTHER
COMMENTS, THAT YOU'D LIKE TO
MAKE, AT THIS CLOSING, WE HAVE
SOME TIME TO ENTERTAIN THAT
BEFORE WE ADJOURN.
>>I DON'T SEE ANYTHING.
I THINK EVERYBODY IS JUST
ANXIOUS TO LEAVE FOR SOME
REASON.
I DON'T KNOW WHY THAT WOULD BE.
WHY WOULD YOU WANT TO GO HOME?
[LAUGHTER]
THANK YOU ALL FOR COMING.
I THINK, DR. GIBBONS, YOU CAN
ADJOURN THE MEETING.